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Transforming growth factor-beta (TGF-β) signaling plays an important role in 
cell-fate determination by dynamically regulating the transcription of genes 
involved in cell proliferation, differentiation and apoptosis. Many of these 
processes are regulated by precise transcriptional control imparted by factors 
like nuclear hormone receptor co-repressor (N-CoR). Acquired resistance to 
TGF-β-induced apoptosis is an important feature of many human malignancies 
including gastric cancer. The molecular mechanism underlying TGF-β-
resistance in gastric cancer cells is presently not known. Preliminary findings 
from our laboratory suggested that the recently identified N-CoR misfolding 
pathway might be linked to TGF-β-resistance in gastric cancer. Therefore, 
identification and characterization of agents that can sensitize gastric cancer 
cells to TGF-β-induced apoptosis could lead to better therapeutic management 
in gastric cancer. One such promising compound is artemisinin, which blocked 
the growth of colorectal cells through inhibiting the hyperactive Wnt/β-catenin 
pathway. Since TGF-β is known to antagonize the growth promoting signal of 
Wnt pathway, it was hypothesized that growth suppressive effect of 
artemisinin might also involve the activation of TGF-β signaling. Based on 
this hypothesis, screening of a selected group of synthetic artemisinin 
analogues was carried out on various gastric cancer derived cell lines and it 
was found that an artemisinin derivative designated as GC011 selectively 
inhibited the growth and promoted apoptosis of TGF-β sensitive gastric cancer 
cells.  
The pro-apoptotic effect of GC011 was apparently mediated through the 
activation of Smad3 and up-regulation of proapoptotic TGF-β target genes 
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PAI-1 and p21. GC011 also imparted a TGF-β-like effect on IgCα promoter 
that contains a consensus TGF-β-responsive element. Moreover, it promoted a 
selective dose- and time-dependent downregulation of N-CoR/HDAC1 in 
TGF-β sensitive cells, suggesting that the GC011-induced up-regulation of 
TGF-β target genes was caused by an abrogation of N-CoR transcriptional 
control. These findings identify GC011 as a possible inhibitor of N-
CoR/HDAC1 function and highlight the therapeutic potential of GC011 as a 
TGF-β analogue in TGF-β sensitive gastric cancer cells. 
However, majority of gastric cancer cells are not sensitive to TGF-β-induced 
growth inhibitory function. Consistent with this characteristic, almost all the 
TGF-β resistant gastric cancer cells displayed lack of sensitivity to GC011.  
This prompted a need to design and develop a novel therapeutic approach that 
could break the barrier of TGF-β resistance and sensitized the TGF-β resistant 
gastric cancer cells to apoptosis by targeting the N-CoR misfolding pathway. 
Our laboratory has previously demonstrated how a misfolded conformation 
dependent loss (MCDL) of N-CoR protein contributed to the pathogenesis of 
APL, AML-M5 and NSCLC cells, suggesting the involvement of generic N-
CoR misfolding pathway in a diverse group of human tumors, including 
gastric cancer. As such, it was hypothesized that an APL-like loss of N-CoR 
due to misfolding might be prevalent in gastric cancer as well, since normal N-
CoR is already recognized to play an important role in the normal 
development of gastric cells. Based on this hypothesis, N-CoR status was 
analyzed in various gastric cancer cells and patient-derived primary gastric 
cancer tissue. N-CoR consistently demonstrated post-transcriptional loss in 
primary and secondary gastric cancer cells. The N-CoR which was subjected 
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to loss in majority of gastric cancer cells displayed the characteristics of 
misfolded N-CoR as seen previously in APL, including aberrant cytosolic 
localization, detergent insolubility, and amplification of ER stress. Cellular 
response to the accumulation of misfolded proteins involves the activation of 
the unfolded protein response (UPR) pathway, whereby components of the ER 
folding machinery and ER-associated degradation (ERAD) are upregulated, 
which eventually refolds the misfolded proteins to their native conformation  
or degrades  the misfolded proteins that cannot be refolded. Proteasome 
inhibition is thought to cause an accumulation of misfolded proteins which 
overwhelm the ERAD pathway resulting in ER stress-induced apoptosis. 
Therefore, it was postulated that blocking the loss of misfolded N-CoR with 
proteasome inhibitor would sensitize the gastric cancer cells to ER-stress 
induced apoptosis.  Based on this hypothesis, the effects of bortezomib, a 
clinical grade protease inhibitor, was investigated in gastric cancer cells. 
Interestingly, bortezomib effectively sensitized the gastric cancer cells to ER 
stress-induced apoptosis by promoting the accumulation of misfolded N-CoR 
via inhibition of its proteosomal degradation by the ERAD pathway. These 
findings suggest that gastric cancer cells have a low threshold for proteosomal 
inihibitor-induced UPR activation and ER stress-induced apoptosis due to the 
loss of misfolded N-CoR protein, and also demonstrate the therapeutic 
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1.1 Gastric Cancer 
1.1.1 Epidemiology 
Although the incidence of gastric cancer has decreased in the last few years, it 
remains a major health problem. Worldwide, almost one million patients are 
newly diagnosed with gastric cancer annually, making it the fourth most 
common malignancy (9% of all cancers). It is also the second leading cause of 
cancer-related mortality, with more than 700,000 patients succumbing to this 
disease every year (10% of all cancer deaths). On the whole, age-standardised 
incidence rates of gastric cancer are higher in men than in women, especially 
more so in middle-aged and elderly groups, with a male to female ratio 
ranging from 1.5 to 3.1 Significant geographical variation in incidence also 
exists. More than two thirds of all cases occur in developing countries - over 
half of the cases occur in East Asia, with China and Japan accounting for 
roughly 41% and 11% of the cases.2  
The two major classification systems used for gastric cancer are the World 
Health Organization (WHO)2 and the Laurén classifications.3 Histologically, 
adenocarcinoma of the stomach is the most common form of all gastric 
malignancies (90-95%). Gastric adenocarcinoma is generally located at two 
main tumor sites, namely proximal (cardia) and distal (noncardia). The  
Laurén classification further divides gastric adenocarcinomas into two 
categories: (1) undifferentiated or diffuse types, and (2) well-differentiated or 
intestinal types.4 These two histological variants appear to have distinctive 
clinicopathological characteristics and are thought to develop via distinct 
molecular pathways. Diffuse type gastric cancers are more prevalent among 
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females and young patients than in males and elderly patients, may be 
multifocal, is not often accompanied by intestinal metaplasia, and can be 
hereditary. It is also more prevalent in low-risk areas. In contrast, intestinal 
type gastric cancers occur more frequently in males and elderly patients, 
predominate in the high-risk areas, and often develop following multifocal 
gastritis accompanied by intestinal metaplasia.2 Other histologies are varied 
and rare, and these include lymphomas (MALToma, 1-5%), gastrointestinal 
stromal tumors (also known as leiomyosarcomas, 2%), carcinoids (1%), 
adenocanthomas (1%), and squamous cell carcinomas (1%).4  
1.1.2 Etiology  
Several factors have been shown to play a contributory role in the etiology of 
this disease. The considerable geographic variability in gastric cancer 
incidences has been attributed to regional dietary practice, where high salt and 
nitrates intake and low fresh fruits and vegetables consumption have been 
associated with increased risk of gastric cancer.5-7 Helicobacter pylori 
infection has also emerged as an important contributing factor, especially in 
the development of intestinal-type adenocarcinoma. In such cases, a sequence 
of prolonged precancerous steps precedes carcinogenesis: chronic gastritis, 
multifocal atrophy, intestinal metaplasia, and intraepithelial neoplasia. H. 
pylori is reported to be the most frequent cause of chronic gastritis.8 Effective 
primary preventive strategies such as improved sanitation, dietary and lifestyle 
changes have resulted in a downward trend of gastric cancer worldwide but 
incidence of proximal gastric cancer has been steadily increasing since the 
1970s. Gastro-esophageal reflux and obesity have been shown to play more 
significant roles in proximal gastric cancer.9 
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However, while H. pylori infection is a well-established risk factor for gastric 
carcinogenesis, only a fraction of infected individuals develop gastric cancer. 
This variable phenotypic expression of infection can be attributed to the 
combined effects of environmental factors, host factors and bacterial virulence 
factors. Several host genetic factors are associated with increased gastric 
cancer risk in patients infected with H. pylori. Human genetic polymorphisms 
in inflammation-related genes, such as interferon-γ receptor 1 (IFNGR1), 
interleukin-1β (IL-1β), interleukin-1 receptor antagonist (IL-RN), toll-like 
receptor 4 (TLR4), and tumor-necrosis factor-α (TNF-α), modulate host 
inflammation response to infection, and thus progression of the disease.10-13 
The presence of bacterial virulence factors, including cytotoxin-associated 
gene (cagA) and vacuolating cytotoxin (vacA), is also associated with gastric 
cancer risk.14 
While most gastric cancer presentations are sporadic, familial aggregation of 
the disease is observed in approximately 10% of the cases, suggesting that 
inherited conditions may also increase risk of gastric cancer. Hereditary 
diffuse gastric cancer (HDGC) is a rare, autosomal dominant inherited form of 
gastric cancer (1-3%), in which approximately 30% of the cases have been 
attributed to germline mutations in the E-cadherin gene (CDH1).15 The 
estimated life-time gastric cancer risk in individuals carrying this mutation is 
as high as 67% in men and 83% in women16. Familial disorders such as Lynch 
syndrome (germline mutations in DNA mismatch repair genes)17 and Peutz-
Jeghers syndrome (germline mutation in STK11 gene)18 may also raise gastric 
cancer risk, although to a lesser extent. In the absence of germline mutations 
in such high penetrance genes, familial clustering of gastric cancer is thought 
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to be a result of the cumulative effect of dietary and environmental risk 
factors, and the genetic susceptibility of these individuals associated with low 
penetrance genes. These unknown genetic defects may include inactivation of 
tumor suppressor genes such as RUNX319 and SMAD4,20 which have been 
implicated in gastric cancer. 
1.1.3 Molecular pathology  
Malignant transformation of gastric cells is a multi-step process which, in 
addition to the host genetic background and environmental exposures, 
involves various genetic and epigenetic alterations in numerous genes. This in 
turn, affects cellular functions that promote cancer cell survival, such as 
apoptosis evasion, sustained angiogenesis, self-sufficiency in growth signals, 
and insensitivity to antigrowth signals.  
Majority of gastric carcinomas are characterized by two distinct genomic 
pathways, chromosomal instability (CIN) and microsatellite instability (MSI). 
Most of the sporadic gastric carcinomas demonstrate CIN, resulting in 
aberrations of chromosome copy number (gains/loss/amplification)21,22 or 
structural chromosome anomalies (translocations/inversions),23,24 which is 
probably the result of failures in either mitotic chromosome transmission or 
the spindle mitotic checkpoint.25  
The remaining gastric carcinomas (10-25%) have defective DNA mismatch 
repair (MMR) systems, presenting with MSI phenotype characterized by 
widespread somatic mutations at coding and non-coding mononucleotide 
repeats.26,27 The human MMR system consists of the proteins hMLH1, 
hMLH3, hMSH2, hMSH3, hMSH6, hPMS1 and hPMS2, and is responsible 
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for repairing DNA replication errors or physico-chemical induced damage. 
Hypermethylation of hMLH1 gene promoter has been associated with 
silencing of hMLH1 protein and microsatellite instability in gastric cancer.28 
As microsatellite regions are particularly susceptible to mutation due to 
slippage of DNA polymerase during DNA replication, a defective MMR 
system may lead to frameshift mutations or protein truncations in genes that 
include or are linked to these microsatellite regions, such as transforming 
growth factor β receptor II (TGFβRII), insulin-like growth factor II receptor 
(IGF-IIR), and BAX.29,30  
1.1.4 Current treatment modalities  
Presently, there is no standard treatment or worldwide consensus for treatment 
of gastric cancer. Different therapeutic strategies are employed in the Western 
and Eastern countries. In western countries, preoperative chemotherapy or 
adjuvant chemoradiotherapy is preferred, whereas Asia favours surgery 
followed by adjuvant chemotherapy. Opinions on lymphadenectomy also 
vary; where D2 lymph node dissection is routine and standardised in Asia, it is 
often not implemented in western countries.31 Surgical resection is the only 
potentially curative treatment at present, where high survival rates have been 
reported in early-stage gastric cancer.32 However, prognosis for gastric cancer 
remains poor as most gastric cancer patients are usually asymptomatic in the 
early stage and are usually undiagnosed until at an advanced stage.33 In such 
cases, surgical resection as a single treatment modality for gastric cancer 
seems to have reached its optimum limit for control and survival of the 
disease.34,35 Preoperative or postoperative strategies which include 
radiotherapy, chemotherapy or both, have been assessed and are currently 
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evaluated in several clinical studies, but median survival is still yet to exceed 
one year in phase III studies.36,37 
Prevention and early detection of the disease are currently not achievable in 
gastric cancer. There are no reliable serum tumor markers recommended for 
use in the diagnosis of gastric cancer, due to the low sensitivity of such 
markers, especially at early stage gastric cancer.38 At present, preventive 
surgery is only limited to individuals with a mutation in the CDH1 gene which 
predisposes them to HDGC,39 as no other genetic markers for gastric cancer 
has been determined. Large, population-based endoscopy screenings 
implemented in high risk incidence areas such as Japan has led to diagnosis at 
an early stage for approximately a third of its gastric cancer patients, but its 
implememtation may be impractical in low risk areas.  
At present, many studies are currently underway to define the biology and 
molecular features of gastric cancer that will help customize treatment. 
Molecular targeting strategies currently investigated include apoptosis 
promoters, cell cycle inhibitors, antiangiogenic agents, and matrix 
metalloproteinases. The number of trials investigating these agents is at 
present limited, but some have shown promising results. While the use of 
gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, has shown 
little clinical activity, promising results have been demonstrated with 
bevacizumab, an anti-VEGF monoclonal antibody, in a small multicenter 
phase II study for the treatment of metastatic disease.40,41 The clinical response 
of another drug, imatinib, a highly selective inhibitor of the receptor tyrosine 
kinase family which targets the platelet-derived growth factor receptor 
(PDGFR), has been demonstrated in metastatic or unresectable gastrointestinal 
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stromal tumors (GIST)42. It is increasingly clear however, that the 
understanding of the underlying biology of gastric cancer may give rise to 
better molecular targets or elucidation of signalling pathways that can be 
modified or blocked by therapeutic intervention. 
1.2 TGF-β signalling pathway  
One of the molecular pathways that may be involved in gastric carcinogenesis 
is the TGF-β pathway. The TGF-β signaling pathway is considered by many to 
be a tumor suppressive pathway, owing to its functions in cell growth 
inhibition and apoptosis. Any alterations or aberration in this pathway results 
in the dysregulation of cellular growth in vivo, which may contribute to 
carcinogenesis. The transforming growth factor-β (TGF-β) family constitutes a 
variety of ubiquitous growth and differentiation factors, which control cell-fate 
determination by dynamically regulating the transcription of genes involved in 
cell proliferation, differentiation, migration and apoptosis. This family 
includes the TGF-βs, bone morphogenetic proteins (BMPs), Nodals, Activins, 
and Anti-Müllerian hormone. There are three isoforms of TGF-β termed TGF-
β1, β2 and β3 in mammals, encoded by different genes but yet employ the 
same receptor signaling systems.43 Of note, TGF-β1 is most frequently up-
regulated in tumor cells and its role in cancer has been frequently studied.44-47 
1.2.1 The canonical TGF-β/Smad signaling pathway 
TGF-βs are synthesized as inactive, latent high-molecular-weight complexes 
which are released as mature, bioactive ligands upon proteolytic cleavage. The 
TGF-β superfamily signals are conveyed through a heteromeric cell-surface 
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complex of two types of transmembrane serine/threonine kinase receptors, 
type I and type II receptors. The type II and type I receptors form hetero-
tetramers composed of two identical TβRII/TβRI receptor heterodimers. The 
bioactive dimeric form of the TGF-β cytokine binds to this hetero-tetramic 
complex, triggering the transphosphorylation of specific serine and threonine 
residues of TβRI by the TβRII kinase. This phosphorylation results in the 
activation of the TβRI kinase that mediates its autophosphorylation and 
phosphorylation of downstream target proteins. With the activation of type I 
receptor kinase, TGF-β initiates various intracellular signaling pathways, 
including the Erk and p38 mitogen-activated protein (MAP) kinase pathways. 
The most established signalling effector pathway triggered by activated TGF-β 
receptors however, is the Smad pathway. Smads belong to a conserved family 
of signal transducers, and consists of conserved N-terminal Mad-homology 1 
(MH1), intermediate linker and C-terminal MH2 domains. The MH1 domain 
drives nuclear translocalization, and contains DNA-binding and protein–
protein interacting sites. The linker domain contains multiple phosphorylation 
sites which allows regulatory phosphorylation by other signaling kinases (e.g. 
mitogen activated protein kinases (MAPKs) or cyclin-dependent kinases 
(CDKs)), and a PY motif, which mediates interaction with Smurf1 and 
Smurf2, E3 ubiquitin ligases that target Smads and Smad-associated TGF-β 
receptors for degradation by the 26S proteasome. The MH2 domain is a major 
protein–protein interaction domain, including phospho-serine-binding activity 
(Fig. 1.1). Activated TβRI specifically recognizes receptor-regulated Smads 
(R-Smads), Smad2 and Smad3, resulting in the phosphorylation of the C-
terminus, which then relieves the inhibition on both N-terminal MH1 domain 
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and C-terminal MH2 domain, resulting in translocation of the Smads to the 
nucleus. En route to the nucleus, Smad2/3 recruits the Co-Smad, Smad4, to 
form heterotrimeric complexes. In the nucleus, activated Smad complex 
associates with DNA binding cofactors, and various coactivators or 
corepressors that will determine the transcriptional effect on a diverse array of 
target genes. Smad6 and Smad7, the inhibitory or I-Smads, can also interact 
with activated type I receptors and therefore function as competitive inhibitors 
of R-Smads activation by the receptors. Also, Smad6 interacts with activated 
R-Smads and inhibits their complex formation with Smad4. The E3 ubiquitin 
ligases, Smurf1 and Smurf2, support the inhibitory activities of I-Smads on 
TGF-β superfamily signalling by mediating the ubiquitination and subsequent 
degradation of R-Smads. Smurfs can also interact with I-Smads and induce 




Figure 1.1. Domain structure of Smads. The general structure-function relationships of the 
different domains of Smads are depicted. The N-terminal and C-terminal domains (termed as 
MH1 and MH2 domains respectively), are conserved between receptor-regulated Smads and 





Figure 1.2. Schematic representation of the TGF-β signal transduction pathway. TGF-β 
binds to the TβRII/TβRI hetero-tetrameric receptor complex. TβRII trans-phosphorylates 
TβRI, which then phosphorylates R-Smads that forms heterotrimeric complexes with Co-
Smad, Smad4, and translocates to the nucleus. In the nucleus, this heterotrimeric Smad 
complex regulates the transcription of target genes, by binding to DNA-binding co-factors 
(X), and co-activators or co-repressors. With TGF-β signaling, I-Smads and Smurfs are also 
exported from the nucleus to form complexes with Smads and receptors, leading to their 
degradation. I-Smads also inhibit phosphorylation of the receptor complex.  
 
1.2.2 Role of TGF-β signalling pathway in gastric cancer 
Dysregulation of the TGF-β signaling pathway has been documented in gastric 
cancer. TGF-β signaling pathway controls a diverse set of cellular processes, 
including cell proliferation, differentiation, migration, and apoptosis.50 
Accordingly, it plays a complex role in the development of cancer, and is 
involved in essentially all six cardinal hallmarks of cancer.53 In general, TGF-
β is known to be a tumor suppressor in the early stage of cancer due to its 
cytostatic and pro-apoptotic effects. On the other hand, TGF-β exerts a pro-
tumorigenic role at advanced stages of cancer, by promoting tumor cell 
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invasion and metastasis through remodeling of tumor matrix, and induction of 
epithelial-to-mesenchymal transition (EMT), tumor angiogenesis, and immune 
suppression.54-57  
Recent studies have demonstrated a strong role for the TGF-β signaling 
pathway in gastric carcinogenesis. Smad2 and Smad4 have been established as 
tumor suppressors in humans, and inactivation of Smad4 is frequently 
observed in human gastrointestinal tumors.58,59 Haploid loss of Smad4 
initiated gastric polyposis and cancer in mice, indicating that loss of 
heterozygosity (LOH) of the SMAD4 locus contributes to the development of 
gastric cancer.20,60 This LOH of the human SMAD4 gene, located on 
chromosome 18q21.1, is frequently demonstrated in not only gastric 
adenocarcinomas, but also in other tumors, including pancreatic and colon 
carcinomas.61 Smad proteins interact with various transcriptional factors 
downstream of the TGF-β signaling pathway, such as Runx, which has shown 
to play a significant role in gastric cancer. Runx3-null mice exhibit gastric 
hyperplasia, and approximately half of human cancers lack Runx expression 
due to hemizygous deletion and DNA methylation of the Runx promoter.19,62 
The role of RUNX3 in gastric carcinogenesis will be discussed further in 
Section 1.3. Structural alterations of the TβRII gene have also been identified 
in gastric cancer cells,63 as well as CpG hypermethylation of its promoter.64  
 
1.3 RUNX3 
Recently, runt-related (RUNX) genes have also been implicated in gastric 
cancer.62 There are three mammalian runt-related genes; RUNX1, RUNX2, and 
RUNX3, all of which are involved in major developmental pathways, and in 
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cell proliferation and differentiation.65-67 Data from various studies suggest 
that RUNX3 is a gastric cancer tumor suppressor,19,62,68 but it still remains to 
be elucidated how Runx3 exerts its tumor suppressor function. 
These runt domain transcription factors are also targets of transforming growth 
factor-β (TGF-β) superfamily signaling, and the RUNX proteins form 
complexes with SMAD2 and SMAD3 that transmit TGF-β signals.69 As 
discussed in Section 1.2.2, various components of the TGF-β pathway have 
been observed to be defective in many human tumors, 55,70 and the pathway is 
considered to be a tumor suppressive pathway in the early stages of 
tumorigenesis, in its dual roles as an inhibitor of cell proliferation and 
promoter of apoptosis.57  
1.3.1 RUNX3 in Gastric Cancer 
The function of RUNX3 as a tumor suppressor was initially reported in gastric 
cancer cells and molecular studies of its function in carcinogenesis had its 
roots in gastric cancer. In April 2002, Li and coworkers reported Runx3 as a 
candidate tumor suppressor in gastric carcinogenesis. Genetic ablation of 
Runx3 displayed profound effects. Runx3-/- mice died soon after birth and the 
gastric epithelia displayed hyperplasia, reduced apoptosis and reduced 
sensitivity to TGF-β-mediated growth inhibition. There was also significant 
correlation between loss of Runx3 and gastric cancer progression stage, from 
40% of Runx3 silencing at early cancer stages to almost 90% as the cancer 
stage progressed. Li et al. only identified one mutation within the conserved 
Runt domain among 116 tumor samples analyzed, but they found that Runx3 
was silenced frequently by hypermethylation of CpG islands in the exon 1 
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region. When they injected gastric cancer cells that overexpressed wild type or 
Runt domain mutated Runx3 into nude mice, they observed that while wild 
type Runx3 mediated a significant reduction in tumorigenicity, the Runt 
domain mutant exacerbated tumor formation. Additionally, cell lines isolated 
from p53 knockout mice were only tumorigenic in nude mice when Runx3 was 
also deleted.62 
Taken together, the above findings strongly suggest that RUNX3 is a tumor 
suppressor whose inactivation is strongly involved in gastric carcinogenesis. 
While the mechanisms underlying the tumor suppressive activity of RUNX3 is 
still far from being fully elucidated, recent studies have thrown up several 
possible mechanisms, among which the TGF-β signaling pathway has 
emerged as a major player.  
1.3.2 Role of RUNX3 in the Tumor Suppressive Effect of TGF-β Signaling 
Pathway in Gastric Cancer 
Hints of a meaningful association between RUNX3 and the TGF-β signaling 
pathway first emerged when it was demonstrated that RUNX3 forms 
complexes with receptor-regulated Smads (R-Smads) that regulate TGF-β 
target gene expression; RUNX3 contacts with the MH2 domains of Smads 
present in their C-terminal conserved region, and Smads appear to interact 
with RUNX3 at two regions of its C-terminal region. It was also shown that 
Smads and RUNX3 work synergistically to regulate TGF-β target genes such 
as the germline IgCα promoter, which contains a TGF-β responsive element. 
These findings strongly suggested that RUNX3 is a downstream target of the 
TGF-β signaling pathway.69 
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The above finding spurred subsequent studies which aimed to elucidate the 
functional relationship between the two. In 2004, Fukumachi et al. reported a 
phenotype of Runx3 knockout mice which provides a tight link between 
Runx3 and TGF-β; hyperplasia and increased proliferation of the gastric 
epithelial cells were observed, and this phenomenon is attributed to the 
reduction in sensitivity to the growth suppressive effect and the apoptotic-
inducing activity of TGF-β. They also showed that RUNX3 expression was 
frequently lost in gastric cancer cells and that exogenous expression of 
RUNX3 in these cells exhibited an inhibition of growth both in vivo and in 
vitro. Through this study, the authors thus demonstrated the involvement of 
RUNX3 in the transmission of signals initiated by TGF-β, as disruption of 
RUNX3 in their experimental model inhibits the action of TGF-β on gastric 
epithelial growth.71 
In 2005, Ito and coworkers studied the expression pattern of RUNX3 in 
human gastric epithelial cells and gastric cancer cell lines and discovered a 
novel cytoplasmic localization of a substantial fraction of RUNX3 in chief 
cells. As a signal transducer, RUNX3 in the cytoplasm is presumed to be in an 
inactive state, and its nuclear import is an essential element in gaining access 
to their target genes. In their studies, Ito et al identified TGF-β as an agent that 
stimulates the nuclear import of RUNX3. Furthermore, in cells that 
demonstrated a cytoplasmic localization of RUNX3, it is known that the 
components of TGF-β signaling pathway are impaired, prompting the 
postulation that perhaps this cascade is primarily involved in regulating the 
nuclear import of RUNX3.19 
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Also in 2005, Chi et al. succeeded in demonstrating that RUNX3 inhibits 
gastric epithelial cell growth by up-regulating p21 gene expression in response 
to TGF-β72. Exogenous RUNX3 expression increased endogenous p21 
expression in response to TGF-β, whereas RUNX3 suppression reduced TGF-
β-induced p21 expression. The p21 promoter was activated by RUNX3, and 
mutations of the Runx-binding sites decreased this activity, thereby indicating 
that p21 is a direct target of RUNX3. RUNX3 was also shown to transactivate 
p21 expression, in cooperation with SMADs. As p21 is one of the downstream 
targets of TGF-β which plays a central role in CDK inhibition and cell cycle 
control, as well as apoptosis, their findings suggested that RUNX3 acts as an 
upstream regulator of p21 expression, through which it inhibits cell growth in 
response to TGF-β.72 
Another group, Yano et al (2006), demonstrated yet another link between 
Runx3 and another TGF-β target gene, Bim. RUNX3 was shown to bind to the 
Bim promoter and physically interacts with a transcription factor 
FoxO3a/FKHLR1, which is involved in apoptosis and cell cycle, to activate 
the expression of the proapoptotic Bim. The gastric epithelia of Runx3−/− mice 
had reduced levels of Bim expression, and of apoptosis, similar to that found 
in Bim−/− mice. Furthermore, in TGF-β−/− mice, levels of Bim expression was 
reduced in the stomach. Their results demonstrated that RUNX3 is responsible 
for transcriptional regulation of Bim in TGF-β-induced apoptosis.73 
Most recently in 2007, a group led by Saeki found that the highly apoptotic 
GASDERMIN (GSDM) was found to be expressed in gastric pit epithelial 
cells but not in gastric cancer cell lines. Its expression is regulated by Lim 
domain only 1 (LMO1), a transcription factor, through a sequence through 
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which RUNX3 binds to in the GSDM promoter. Additionally, they observed 
that TGF-β up-regulated both the expression of LMO1 and GSDM in the 
gastric epithelial cell lines, and apoptosis was induced. Taken together, their 
findings again pointed out the involvement of RUNX3 in the induction of 
TGF-β-induced apoptosis.74 
As such, there is a significant amount of data that demonstrates strong 
functional cooperation between RUNX3 and the TGF-β signaling pathway in 
gastric cancer. However, even with the current existing data, the mechanism of 
action of RUNX3 in the tumor suppressive activity of the TGF-β pathway still 
remains to be clarified. 
Association 
Proposed Functional 
Cooperation       
Reference 
RUNX3 contacts the MH2 domains of 
Smad 1 and Smad3 present in their 
conserved C-terminal regions; 
interaction synergistically activates 
germline promoter IgCα. 
RUNX3 is a downstream 
target of TGF-β signaling 
pathway. 
69 
In Runx3-/- mice, hyperplasia of 
glandular stomach epithelial cells 
observed, due to a reduced sensitivity to 
the cell growth inhibitory and 
apoptosis-inducing activity of TGF-β.  
RUNX3 is a possible 
tumor suppressor, and 
contribute to the tumor 
suppressive effect of TGF-
β pathway. 
62 
Runx3-/- gastric epithelial cells resistant 
to apoptosis-inducing action of TGF-β; 
exogenous expression of RUNX3 
caused growth inhibition in vitro and in 
vivo. 
RUNX3 plays an essential 
role in transmitting signals 
initiated by TGF-β, as 
disruption of RUNX3 
inhibits the action of TGF-
β on gastric epithelial 
growth. 
71 
A substantial fraction of RUNX3 was 
found to reside in the cytoplasm in chief 
cells, as an apparently nonfunctional 
form; and TGF-β was found to stimulate 
nuclear translocation of RUNX3.  
The non-functional, 
cytoplasmic state of 
RUNX3 observed in many 
gastric cancer cells may be 
due to an impaired TGF-β 




RUNX3 binds to and activates p21 
promoter; RUNX3 is required for TGF-
β-dependent induction of p21 
expression in stomach epithelial cells; 
RUNX3 induces p21 expression in 
cooperation with TGF-β specific 
SMADs. 
 
RUNX3 is the upstream 
regulator of p21 
expression, through which 
it inhibits cell growth in 
response to TGF-β. 
72 
RUNX3 binds to Bim promoter, and 
interacts with FoxO3a to activate Bim 
expression; Runx3-/- gastric epithelia 
had reduced levels of Bim expression, 
and apoptosis, similar to Bim-/- mice; 
levels of Bim reduced in TGF-β-/- mice. 
RUNX3 is responsible for 
the transcriptional up-
regulation of Bim in TGF-
β-induced apoptosis. 
73 
Proapoptotic GASDERMIN (GSDM) 
was found to be suppressed in gastric 
cancer cell lines and primary gastric 
cancers; Lim domain only one (LMO1) 
regulates GSDM expression through a 
sequence to which RUNX3 binds in 
GSDM promoter region; TGF-β up-
regulates LMO1 and GSDM expression 
and induces apoptosis. 




Table 1.1. Functional cooperation between RUNX3 and TGF-β-induced tumor 
suppressive pathway 
 
1.4 The nuclear receptor co-repressor (N-CoR)  
1.4.1 The nuclear receptor co-repressor (N-CoR) is a key component of the 
generic multi-protein complex involved in transcriptional control. 
Nuclear receptors such as thyroid-hormone and retinoic-acid receptors (TR, 
RAR) are ligand-dependent transcription factors that play an essential role in 
the regulation of growth, development and homeostasis by regulating gene 
expression. Nuclear receptors interact with a wide array of co-regulator 
molecules termed as co-activators and co-repressors. While co-activators are 
generally recruited to nuclear receptors upon ligand binding to promote gene 
transcription, co-repressors mainly bind to un-liganded nuclear receptors and 
repress gene transcription of targets.75 One of the first nuclear receptor co-
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repressors identified is nuclear receptor co-repressor (N-CoR), a 270-kDa 
protein which interacts with both thyroid hormone and retinoic-acid receptors 
and mediates ligand-independent transcriptional repression.76 N-CoR can also 
interact with steroid hormone receptors, estrogen receptor (ER) and 
progesterone receptor (PR), in the presence of their antagonists, suggesting a 
role for N-CoR in mediating the antagonist-associated effects of steroid 
hormone receptors.77,78  
N-CoR contains multiple repression domains (RDs), nuclear receptor 
interaction domains (NRIDs) and Swi2/Ada2/N-CoR/TFIIID (SANT) motifs 
(Fig. 1.3). This large protein serves as a large docking surface for various 
components of the repression machinery to tether to for transcriptional 
repression. As such, N-CoR exists in large assemblies with an apparent 
molecular weight of between 1.5 to 2 MDa.79 N-CoR complexes are 
associated with multiple histone deacetylase (HDAC) enzymes, suggesting 
that N-CoR-mediated transcriptional repression involves chromatin 
remodeling via the deacetylation of nucleosomal histones.79-82 N-CoR also 
forms a complex with mammalian Sin3 orthologs, which together with 
HDACs, forms a complex which is required for transcriptional repression by 
thyroid hormone receptor and tumor suppressor Mad.80,83  
Several studies have also implicated N-CoR in repression by its interaction 
with unrelated transcription factors, which regulate diverse cellular processes. 
One such factor is ETO, the fusion partner of t(8:21) acute myeloid leukemia 
(AML). The interaction of the fusion AML1/ETO with the N-CoR complex 
results in the disruption of normal hematopoiesis by the transcriptional 
repression of the AML1-responsive genes.84 Kaiso, a methyl binding CpG 
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protein belonging to the BTB/POZ family of transcription factors, has also 
been shown to bind to the N-CoR repressor complex, demonstrating the 
involvement of N-CoR in DNA methylation-mediated biological functions.85 
It was also demonstrated that BCL6 (B-cell lymphoma-6) transcriptional 
repressor modulates survival of tumor cells in diffuse large B-cell lymphomas 
(DLBCLs) via the recruitment of the N-CoR repressor complex to BCL6 
target genes involved in survival and proliferation such as ATR and TP53.86,87  
 
Figure 1.3. The domains of N-CoR. The interaction domains for HDAC lie within the 
repression domains (RI, RII, RIII) of N-CoR. The histone-binding SANT domains (A and B), 
and interaction domains for nuclear receptors (I and II), PML, Ski and other transcription 
factors are highlighted.  
 
N-CoR play important physiological roles in development, differentiation, and 
carcinogenesis. Studies with N-CoR knockout mice demonstrated the 
importance of N-CoR in early embryonic development. Murine knockouts of 
N-CoR are embryonically lethal and observed phenotypes in N-CoR-deficient 
mice include defects in T cell development and lower thymocyte counts, 
smaller livers and overall size, defects in neural development, and anemia due 
to defects in erythrocyte development.88,89 N‑CoR also regulates neural stem 
cell differentiation as cytoplasmic translocation of N‑CoR leads to astrocytic 
differentiation.90 Also, N-CoR plays a role in myogenesis by regulating 





1.4.1 N-CoR plays a role in carcinogenesis 
A well-established oncogenic role for N-CoR has been elucidated in acute 
promyelocytic leukaemia (APL). APL, which is caused by a block in myeloid 
differentiation, is associated with rearrangements of RAR-α, which results in 
fusion between the RAR-α gene and the promyelocytic leukemia gene (PML) 
or the promyelocytic leukemia zinc finger gene (PLZF).92 Both RAR-α fusion 
proteins recruit the N-CoR repressor complex which blocks differentiation of 
hematopoietic precursors.93  
In acute myeloid leukemias (AML) which result from the t(8;21) translocation 
between AML1 and ETO, the AML1-ETO fusion protein also recruits the N-
CoR-histone complex resulting in the transcriptional repression of AML1 
target genes involved in normal hematopoiesis.84 
Dysregulation of N-CoR and its subsequent loss of function as a repressor also 
contribute to carcinogenesis. Phosphorylation of N-CoR by IKKα in colorectal 
cancer cells results in a nuclear export of N-CoR, relieving its repressive 
effects and thereby promoting the survival of these cells.94 Also, loss of N-
CoR protein expression in thyroid tumor cells has been shown to promote 
PI3K signaling pathway, thus contributing to tumor progression.95 
1.4.2 N-CoR and its involvement in TGF-β signaling pathway 
It was first established that Ski/SnoN (Ski-related novel protein N) directly 
binds to N-CoR and mSin3A to form a complex with HDAC.83 It was later 
shown that Ski/SnoN also physically interacts with Smad3 and Smad4, 
displacing the co-activator p300/CBP from the Smad proteins and recruiting 
the N-CoR/HDAC complex. This repressor complex is then recruited to 
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Smad-binding elements (SBE) in the promoters of TGF-β-responsive genes in 
a ligand-dependent manner, resulting in the repression of TGF-β target genes 




Figure 1.4. Mode of action of N-CoR-mediated repression on Smad target genes. It has 
been shown that Ski/SnoN directly binds to N-CoR, MeCP2 and mSin3A to form a complex 
with HDAC. Upon binding of Ski/SnoN to Smads, Ski/SnoN displaces the activator complex 
p300/CBP and recruits the repressor complex containing N-CoR to Smad target genes, thereby 
repressing transcription of these genes.  
 
1.5 Artemisinin 
Artemisinin (Fig. 1.5) is a sesquiterpene lactone containing a 1,2,4-trioxane 
structural motif. This endoperoxide compound is isolated from the Chinese 
plant Artemisia annua (more commonly known as qinghaosu or sweet 
wormwood) and has been used by Chinese traditional medicine practitioners 
for over two millennia for the treatment of fever and malaria.99,100 Artemisinin, 
and its bioactive derivatives such as artesunate (ART) and dihydroartemisinin 
(DHA) are newer generation FDA-approved anti-malarial drugs used in the 
clinical management of malaria, including multidrug-resistant strains. The 
peroxide group within the trioxane bestows potent antimalarial activity on 
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these compounds, by its cleavage in the presence of iron leading to generation 
of free-radical reactive oxygen species (ROS)99. These compounds 
demonstrate excellent parasiticidal activity at plasma concentrations well-
tolerated by the host cells.99-103 
 
Figure 1.5. Artemisinin and its derivatives dihydroartemisinin and artesunate. 
The active pharmacophore is the peroxide bridge that bestows antimalarial activity, 
and the derivatives are now widely used for treatment of malaria. GC011 is a newer 
derivative prepared from dihydroartemisinin that possesses potent antimalarial 
activity in in vitro screens. The pyrimidinylpiperazinyl unit attached to C10 in GC011 
confers enhanced lipophilicity as compared to artemisinin and the derivatives 




1.5.1 Anticancer properties of Artemisinin 
In addition to anti-malarial activity, artemisinin and its derivatives also 
demonstrate remarkable anti-tumor activity against a variety of tumor cells.104-
107 An analysis of 55 cancer cell lines by the Developmental Therapeutics 
Program of the National Cancer Institute (NCI), USA, showed that artesunate 
displays strong inhibitory activity against leukemia and colon cancer cells, and 
intermediate activities on melanoma, breast, ovarian, prostate, central nervous 
system (CNS), and renal cancer cells.108 Antitumor activity has also been 
reported in cancer patients109,110 and a phase II study with advanced non-small 
cell lung cancer (NSCLC) patients reported improved short-term survival rate 
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and time-to-progression rates of patients with artemisinin combination 
treatments.111  
In general, cancer cells exposed to these derivatives demonstrate decreased 
proliferation, induction of apoptosis, and inhibition of angiogenesis and 
migratory properties. Studies have identified several mechanisms by which 
artemisinins exert their antitumor activities. One study showed that both ART 
and DHA inhibited cell proliferation in hepatoma cells by inducing G1-phase 
arrest, via their action on key cell cycle regulatory proteins such as cyclin D1, 
cyclin E, and p21.112 DHA treatment also promoted apoptosis in acute 
promyeloid leukemia cells and Jurkat T-lymphoma cells via its regulation of 
pro-apoptotic proteins Bax and Bak, and anti-apoptotic protein Bcl-2.113-115 
DHA also demonstrated antiangiogenic properties by targeting vascular 
endothelial growth factor (VEGF) in human umbilical vein endothelial cells 
(HUVEC) via the NF-kB pathway.116,117 Another group reported the inhibitory 
effects of artemisinin on migratory abilities of metastatic melanoma cells by 
downregulating metalloproteinase-2 (MMP-2) and αVβ3 integrin 
expression.118 
However, little is known of the mechanism underlying its pharmacological 
activity in cancer. One proposed mechanism is cleavage of the endoperoxide 
bridge by iron in the cancer cells, which possess higher influx of iron via 
transferrin receptors, resulting in generation of ROS and other free radicals.112 
This is similar to the action of artemisinins on malarial parasites. Generation 
of radicals may therefore play a role in the antitumor effects reported in 
artemisinin-treated cancer cells, such as enhanced apoptosis, growth arrest, 
inhibition of angiogenesis, and DNA damage. However, studies show that the 
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lack of the endoperoxide moiety does not completely diminish anticancer 
activity of artemisinin, suggesting that not all of its anticancer activities may 
be caused by the global toxic effects of oxidative damage.119 Alternative 
peroxide-independent mechanisms may contribute to its activities. 
 
1.6 ER stress and the unfolded protein response  
1.6.1 Protein folding and modification in the endosplamic reticulum (ER) 
The ER is the entry site for proteins destined for secretion or insertion into 
cellular membranes. The lumen of the ER provides an oxidative environment 
containing high calcium levels for the early steps in the maturation of these 
proteins to take place in the ER - the folding of the nascent polypeptide chains 
and posttranslational modifications of the proteins important for correct 
folding of proteins, such as N-linked glycosylation and disulphide bond 
formation. Proteins destined for translocation to the ER are usually recognized 
by a cytosolic ribonucleoprotein complex, the signal recognition particle 
(SRP), typically via amino terminal signal sequences on the nascent proteins. 
The resulting ribosome-nascent chain-SRP complex then binds to the SRP 
receptor on the ER membrane, whereby the SRP dissociates and the ribosome-
nascent chain is then directed to a proteinaceous core in the membrane called 
Sec61 translocon, which allows the translocation of the growing polypeptide 
chain across the membrane and into the ER.120-122 
As the polypeptide enters the lumen of the ER, its proper folding is mediated 
by a range of ER resident chaperones and folding enzymes. These folding 
factors include heat shock proteins acting as chaperones such as glucose-
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regulated protein of molecular weight 78 kDa (GRP78), oxidoreductases such 
as protein disulphide isomerase (PDI) and ERp57, and glycan-binding proteins 
such as calnexin and calreticulin. GRP78 is a highly expressed ER resident 
chaperone which binds to the ER through an N-terminal cleaved signal peptide 
and a C terminal ER retention motif (KDEL). The C-terminal domain of 
GRP78 binds to exposed hydrophobic regions of protein folding intermediates 
with low affinity in an ATP-bound state, which becomes more stable upon 
ATP hydrolysis. GRP78 returns to a low-affinity peptide-binding state upon 
exchange of ATP for bound ADP. As such, protein binding is coupled to 
cellular energy expenditure in this manner.123 
The ER lectins calnexin and calreticulin bind to partially folded 
monoglucosylated N-linked glycans together with ER-resident oxidoreductase, 
ERp57.124 Binding and release from the calnexin/calreticulin is determined by 
monoglucosylation of the glycans, and proteins only leave this cycle once the 
side chains are no longer monoglucosylated. This on-and-off cycle is mediated 
by two independent ER enzymes; glucosidase II and UP-glucose glycoprotein 
glucosyl transferase (UGGT). Glucosidase II hydrolyses the glucose from the 
monoglucosylated core glycan for dissociation from calnexin/calreticulin, 
whereas UGGT glucosylates the incompletely folded proteins for reassociation 
with calnexin and calreticulin. This cycle of glucosylation and deglucosylation 
continues until the glycoprotein has reached its native conformation or is 
targeted for degradation. Only correctly folded proteins are exported to the 
Golgi, whereas incompletely folded proteins are either retained in the ER or 
targeted for degradation. PDI binds to unfolded proteins with high affinity and 
targets them for export to the cytosol via the Sec61 translocon, for refolding or 
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degradation.125 For degradation, a single mannose residue is removed by the 
ER α1,2-mannosidase I, and associates with ER degradation-enhancing α-
mannosidase-like protein (EDEM).121  
Physiological conditions prevailing in the cell and changing environmental 
factors may interrupt the protein folding process of newly synthesized chains 
or promote loss of native conformation in mature polypeptides, leading to the 
problem of misfolded protein aggregration. To counteract this problem, cells 
evolved a sophisticated system of molecular chaperones, which protects 
nascent proteins during folding. These cytosolic chaperones include heat 
shock protein 70 (Hsp70), Hsp100, small heat shock proteins (sHSPs), and 
chaperonins such as TRiC (TCP-1 ring complex), with roles in protein 
refolding and aggregation prevention.126,127 Another two chaperones, HSC70 
and HSP90 work as a single multichaperone system which, in addition to a 
role in protein folding, also function in protein sorting to intracellular 
organelles, or proteasome for degradation. This system removes misfolded 
proteins through interactions with co-chaperones CHIP (carboxyl terminal of 
HSC70-interacting protein), which promotes ubiquitylation and degradation of 
HSC70-HSP90 substrate polypeptides, and BAG1 (BCL2-associated 
athanogene-1), which mediates contact with the proteasome.128  
1.6.2 ER stress and the Unfolded Protein Response (UPR) 
In cases where demands on the ER protein folding machinery exceeds its 
capacity, resulting in the accumulation of unfolded or misfolded proteins in 
the ER, a condition called “ER stress” occurs. Multiple pathologic stimuli can 
cause the accumulation of proteins in the ER, such as hypoxia, glucose 
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deprivation, oxidative stress, expression of mutant proteins and overexpression 
of some wild-type proteins.129 To alleviate ER stress and re-establish ER 
homeostasis, a group of signal transduction pathways collectively called the 
unfolded protein response (UPR) is activated. The UPR has two primary 
functions: 1) to restore homeostasis by downregulating transcription and 
translation of proteins, activating signalling pathways to increase production 
of molecular chaperones involved in protein folding and increasing the 
removal of misfolded proteins via the ER-associated degradation (ERAD) 
pathway130 or autophagy131,132 and 2) to initiate apoptotic pathways if ER 
stress persists or is prolonged.133 The latter reflects the cytotoxic branch of 
UPR while the former represents the cytoprotective branch of UPR. 
UPR generally involves three signalling pathways originating from the ER, the 
inositol requiring kinase 1 (IRE-1) pathway, the PKR-like ER kinase (PERK) 
pathway, and the activating transcription factor 6 (ATF6) pathway (Fig. 1.6). 
IRE-1, PERK and ATF6 are integral ER proteins and function as ER stress 
sensors, and are activated upon dissociation with GRP78. As misfolded 
proteins accumulate in the ER, sequestration of GRP78 from these proximal 
sensors allows their dimerization and activation.134  
The most immediate response to the accumulation of unfolded or misfolded 
proteins is the activation of PERK. PERK, a type I transmembrane kinase, 
upon release from GRP78, autophosphorylates itself following 
oligomerization, thereby triggering its serine-threonine kinase activity. 
Activated PERK then phosphorylates eukaryotic initiating factor 2 subunit α 
(eIF2α), which shuts off general protein translation. Phosphorylated eIF2α 
promotes the translation of some mRNAs however, such as ATF4, which then 
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induces expression of ER chaperones to alleviate ER stress. Under prolonged 
or severe ER stress, ATF4 also induces GADD34 and C/EBP homologous 
protein (CHOP), proteins involved in ER stress-induced apoptosis.130  
Upon dissociation from GRP78, IRE-1, a type I transmembrane protein 
containing both a serine-threonine kinase domain and an endoribonuclease 
domain, homodimerizes and autophosphorylates itself, activating its 
endoribonuclease activity. This results in its cleavage of X-box-binding 
protein 1 (XBP1) mRNA, and due to a frameshift, produces a spliced form of 
XBP1, a functional 41-kDa basic leucine zipper (bZIP) family transcription 
factor that induces transcription of UPR- and ERAD-related genes. IRE1 also 
binds the RING finger protein TRAF2, leading to phosphorylation and 
activation of apoptosis signal-regulating kinase 1 (ASK1). This in turn leads to 
phosphorylation and activation of JNK, which has been reported to inhibit 
anti-apoptotic BCL2 by phosphorylation.135 
ATF6 is a type II transmembrane protein which, upon dissociation from 
GRP78, translocates to the Golgi, where it is cleaved by Golgi-resident serine 
proteases, site 1 and site 2 proteases (S1P and S2P) to release its cytosolic 
domain. This cytosolic domain moves into the nucleus and induces expression 
of gene targets including ER chaperones such as GRP78, calnexin and 
calreticulin, foldases such as PDI, and ERAD components.123,136  ATF6 can 
also induce CHOP mRNA expression, although no link to ER stress-induced 





Figure 1.6. The Unfolded Protein Response (UPR). Upon ER stress due to 
accumulation of misfolded proteins results, GRP78 dissociates from the proximal ER 
sensors, thereby triggering UPR via the activation of the PERK, ATF6 and IRE-1 
pathways.  
 
1.6.3 UPR-induced apoptosis 
It is apparent that the UPR has both cytoprotective and cytotoxic effects. 
Under chronic ER stress conditions where the cytoprotective pathway of UPR 
fails to correct the folding defect, UPR-induced apoptosis may occur. The 
IRE1-ASK1-JNK pathway has been implicated in ER stress–induced cell 
death, by promoting the activation of proapoptotic BCL-2 family protein BIM 
and inhibiting anti-apoptotic BCL-2 family protein BCL2.135 Additionally, the 
PERK pathway, via its activation of ATF4, and the ATF6 pathway, 
upregulates proapoptotic CHOP.135 While the PERK and the IRE-1 pathways 
can initiate pro-apoptotic signal during prolonged ER stress, it is the activation 
of downstream molecules that commit the cells to ER stress-induced 
apoptosis. CHOP-induced apoptosis involves the activation of BIM and 
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GADD34, and downregulation of BCL-2.138,139 GADD34, a protein 
phosphatase 1 (PP1)-interacting protein, induces PP1 to dephosphorylate 
eIF2α, thus relieving the translational block mediated by PERK. Although 
GADD34 has been shown to correlate with apoptosis, the underlying 
mechanism is still unknown. GADD34 might induce apoptosis through its 
inhibition of eIF2α phosphatases.137  
The execution phase of ER stress-induced apoptosis is caspase activation. 
There are two major pathways of apoptosis. The intrinsic (mitochondrial) 
pathway is regulated by a balance between proapoptotic BH3-only proteins 
such as BAK and BAX and antiapoptotic proteins, such as BCL2. Bak and 
Bax oligomerize and are inserted into the outer mitochondrial membrane, 
forming a pore for the release of cytochrome c. Cytochrome c then promotes 
the formation of the apoptosome between Apaf-1 and procaspase-9, leading to 
caspase-9 activation, and ultimately, caspase 3. The extrinsic (death receptor) 
pathway on the other hand, responds to extracellular stimuli, involves 
clustering of death receptors, recruitment of procaspase-8 and formation of a 
death-inducing signalling complex (DISC), resulting in the activation of 
caspase-8 and subsequent caspase cascade leading to apoptosis. ER stress-
induced apoptosis appears to act via the intrinsic pathway, although some 
recent studies have implicated the involvement of the extrinsic pathway. The 






1.6.4 UPR as a possible target in cancer therapy 
Tumor cells are constantly under stressful stimuli such as hypoxia, glucose 
deprivation, insufficient ER energy supply, pH changes, and viral infection. 
Additionally, they can express mutant proteins. All of these can cause ER 
stress and UPR has been shown to provide survival pathways for tumor 
growth.141-143 Increased expression of UPR components in various cancers 
were reported, such as XBP1, ATF6, CHOP, GRP78/BiP.143,144 On the other 
hand, most normal cells are not subject to stress and their UPR pathway are in 
a quiescent state. This discrepancy between normal and tumor cells raises the 
possibility of specifically targeting tumor cells by UPR targeting agents. One 
therapeutic approach is to induce the accumulation of misfolded protein in the 
ER to overwhelm the UPR, and promote the switch from cytoprotective UPR 
to cytotoxic UPR. This may be achieved by inhibition of the proteosomal or 
autophagic degradation of misfolded proteins retrotranslocated from ER to the 
cytosol. Another approach is to inhibit components of the UPR so that tumor 
cells cannot cope with the stressful conditions, ultimately leading to cell death 




Figure 1.7. Targeting the UPR for anticancer therapeutics. The UPR is an 
attractive target for cancer therapeutics. Activation of cytoprotective UPR pathway 
promotes survival of tumor cells whereas strong ER stress activates cytotoxic UPR, 
leading to cell death.  Modulation of the activation of UPR pathways to drive the cells 
towards the death pathway could be achieved by inhibiting components of the UPR 
so that cancer cells cannot cope with the stressful environment which then results in 
cell death. Another approach is to increase the stress on the tumor cells by inhibiting 
the clearance of misfolded or unfolded proteins in the ER, either via inhibiting 
proteosomal degradation or autophagic degradation. As a result, ER stress is 












1.7 Inhibition of proteasome degradation as a therapeutic strategy in 
cancer 
1.7.1 The Ubiquitin-Proteosome Pathway (UPP)  
Degradation of proteins plays an important role in regulation of cellular 
functions and homeostasis. In eukaryotic cells, this role is carried out by the 
ubiquitin-proteasome pathway (UPP), which is comprised of an ubiquitin 
conjugating system and a 26S proteasome.145 UPP substrates include cellular 
proteins involved in cell-cycle regulation,146 oncogenesis,147 and apoptosis.148 
The UPP also selectively removes mutant, misfolded, damaged or obsolete 
proteins for the maintenance of cellular homeostasis.149  
The 26S proteasome is a proteolytic complex comprised of a multi-catalytic 
20S core flanked by two 19S regulatory caps. The 20S catalytic core contains 
the proteolytic activities of the proteasome, namely the chymotrypsin-like, 
trypsin-like, and caspase-like activities. The 19S subunits regulate entry of 
ubiquitinated proteins into the hollow chamber of the 20S core.150 Briefly, 
proteosomal degradation of proteins proceeds as follows: 1) Tagging of target 
proteins with polyubiquitin molecules in an ATP-dependent manner through 
E1, E2, and E3 ligases. 2) Polyubiquitinated proteins are recognized by the 
19S regulatory caps and directed into the 20S catalytic core for degradation, 
generating peptides 3-25 amino acids in length. 3) Ubiquitin molecules are 




Figure 1.8. The UPP pathway. The attachment of ubiquitin to the target proteins 
requires involves a series of ATP-dependent enzymatic steps by E1 (ubiquitin 
activating enzyme), E2 (ubiquitin conjugating enzyme) and E3 (ubiquitin ligating 
enzyme). E1 binds ubiquitin, which is transferred to E2. E3 then transfers ubiquitin to 
target protein. The 26S proteosome recognizes polyubiquitinated protein, which leads 




1.7.2 Proteosome inhibition as an anticancer therapy 
As mentioned earlier, one of the functions of the UPP is the degradation of 
misfolded or unfolded proteins. Detection of misfolded proteins trigger the ER 
stress and the induction of the UPR pathway, resulting in the degradation of 
the proteins by the 26S proteasome via the ERAD pathway.152 Inhibition of 
the proteolytic activity of the proteasome may cause the accumulation of 
misfolded or unfolded proteins, and results in constitutive ER stress that 
switches on the cytotoxic UPR pathways leading to cell death.153  
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It was reported in several studies that proteasome inhibitors are more cytotoxic 
in cancer cells than normal cells.153-156  As cancer cells are more likely to have 
defective or mutant proteins and thus increased accumulation of misfolded 
proteins, it may be more dependent on the proteosomal degradation process. 
Addtionally, as many proteins involved in cell cycle control and apoptosis are 
degraded by the proteosome, it follows that these cellular processes may be 
affected by proteasome inhibition. As such, proteosome inhibition presents an 
attractive strategy for anticancer therapy. 
Proteosome inhibitors can exist as naturally-occurring compounds, such as 
lactacystin and epoxyketones, or as synthetic compounds, such as the peptide 
aldehyde MG132.157 These synthetic compounds generally target the 
chymotrypsin-like activity of the proteasome.158 However, as these 
compounds are not sufficiently selective inhibitors of proteosome, dissociate 
quickly from the proteasome, or are removed by the multi-drug transporter 
system, they may not be suitable for clinical use.159   
To circumvent this problem, the aldehyde group of synthetic inhibitors was 
replaced with boronic acid. Bortezomib (N-pyrazinecarbonyl-L-
phenylalanine-L-leucine boronic acid, originally known as PS-341 and 
marketed as Velcade by Millennium Pharmaceuticals), a boronic acid 
dipeptide, has been found to be a potent and specific inhibitor of the 26S 
proteasome. This specificity is due to the bond formation between the boronic 
acid moiety of bortezomib and the nucleophilic hydroxyl side chain of Thr1 in 
the S1 pocket of the β5 subunit of the proteasome.160 It is the first and only 
proteasome inhibitor that has been U.S Food and Drug Administration (FDA)-
approved as treatment for cancer, that is of newly diagnosed multiple 
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myeloma, relapsed/refractory multiple myeloma, and mantle cell 
lymphoma.161-163 Bortezomib, either on its own or in combination with other 
drugs, has an overall positive clinical response.164,165 
1.7.3 Mechanism of action of Bortezomib 
Bortezomib has demonstrated anticancer properties in a variety of cancer cells 
including multiple myeloma, prostate cancer, pancreatic cancer, renal cell 
carcinoma, gastric cancer and squamous cell carcinoma.164,166-170 Several 
possible mechanisms of action has been proposed for the anticancer properties 
of bortezomib. In myeloma cell lines, it was found that bortezomib induced 
gene expression of components of the UPR such as HSP70, calreticulin and 
BAG3. The induction of ER stress results in calcium release, leading to 
cytochrome c release from the mitochondria and activation of caspases, 
followed by cleavage of Bid to tBid.171 Another group reported that 
bortezomib-triggered apoptosis in multiple myeloma cells is dependent on 
caspase-2 activation. Caspase-2, which is associated with ER stress, can serve 
as a proximal caspase that functions upstream of mitochondrial signalling 
during ER stress-induced apoptosis by bortezomib in multiple myeloma 
cells.172 Another study described the suppression of the pro-survival nuclear 
factor-κB pathway by the inhibition of proteasome by bortezomib in multiple 
myeloma cells.173,174 The molecular sequelae of proteasome inhibition by 
bortezomib in multiple myeloma cells was also investigated, revealing a shift 
of balance between proapoptotic and antiapoptotic genes to induce or increase 
sensitivity to apoptosis, up-regulation of heat-shock proteins and 
ubiquitin/proteasome pathway members, and the triggering of both extrinsic 
and intrinsic apoptotic pathways.175 As multiple myeloma cells produce and 
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secrete abundant immunoglobulins (Igs), it is very likely that they are more 
susceptible to ER stress induction and proapoptotic UPR. This might explain 
its sensitivity to the proteasome inhibitor bortezomib.176 
Other than proteasome inhibition, other mechanisms by which bortezomib 
may exert its anticancer activity have been proposed. For example, bortezomib 
has been reported to induce pro-apoptotic NOXA,177 and reduce pro-survival 
hypoxia-inducible factor-1α (HIF-1α).178  
With the FDA approval of bortezomib as a front-line treatment for cancer, it is 
increasingly clear that the UPP is a viable therapeutic target. Although other 
mechanisms may be also be responsible for the antitumor effects of 
bortezomib, the proteasome inhibitory effect of bortezomib may prove to be 
highly efficacious in malignant cells in which the ER is already predisposed to 














1.8 Hypotheses and Objectives 
Artemisinin, a sesquiterpene lactone isolated from the plant Artemisia annua, 
is recognized as a newer generation of anti-malarial drugs which demonstrates 
excellent larvicidal activity at plasma concentrations that are well-tolerated by 
the host cells. In addition to the anti-malarial activity, artemisinin also 
demonstrated remarkable anti-tumor activity against a variety of tumor cells. 
The molecular mechanism underlying its anti-tumor effect is thought to be 
similar to its anti-malarial activity, which is based on the endoperoxide bridge 
that reacts with haem molecules and generates potentially cytotoxic free 
radicals that promote cell death. Artemisinin has recently been shown to arrest 
the growth of human colorectal carcinoma cells through attenuating the 
hyperactive Wnt/β-catenin pathway. Since TGF-β acts as a natural antagonist 
of Wnt signaling, therefore, it is likely that artemisinin-induced growth 
inhibition may also involve an activation of genes regulated by TGF-β 
pathway. Based on this hypothesis, the aims of this project are to investigate 
whether artemisinin could induce any growth suppressive effect on gastric 
cancer cells, and elucidate the mechanism underlying such effect, if any.  
Our laboratory has previously demonstrated how a misfolded conformation 
dependent loss (MCDL) of N-CoR protein contributed to the pathogenesis of 
APL cells. It is hypothesized that an APL-like MCDL of N-CoR might be 
prevalent in gastric cancer as well. In eukaryotes, the accumulation of 
misfolded proteins in the endoplasmic reticulum typically results in the 
induction of a stress signalling pathway known as the unfolded protein 
response (UPR). To prevent the accumulation of misfolded protein, UPR 
induction includes the downregulation of general protein synthesis and 
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increased transcription of components of both ER folding machinery and 
degradative machinery. Misfolded proteins which cannot be properly refolded 
are targeted for ER-associated degradation (ERAD), which involves the 
retrograde translocation of the proteins from the ER and subsequent 
degradation by the 26S proteasome, a large ATP-dependent protease. When 
the stress is prolonged, the cytotoxic UPR is activated instead, eventually 
leading to UPR-induced apoptosis. Thus, treatment with proteosome inhibitors 
would result in the accumulation of misfolded proteins within the ER, which 
would then elicit ER stress response and UPR, eventually leading to the 
induction of apoptosis. With these hypotheses in mind, this project also aims 
to evaluate the potential of proteasome inhibition, specifically that of 































2.1 Materials  
2.1.1 General Reagents and Kits 







4’,6-diamidino-2-phenylindole (DAPI) Sigma Aldrich MO,USA 
1 kb DNA ladder Promega WI,USA 
100 bp DNA ladder Promega WI, USA 
30% Acrylamide-Bis Solution Bio-Rad CA, USA 
Agarose Bio-Rad CA,USA 
Ammonium Persulfate Bio-Rad CA,USA 
Ampicillin Sigma Aldrich MO,USA 
Annexin V-FITC Apoptosis Detection Kit BD Pharmingen CA,USA 
Bovine Serum Albumin (BSA) Sigma Aldrich MO,USA 
Bromophenol Blue Sigma Aldrich MO,USA 




CellTiter 96® AQueous One Solution Cell 
Proliferation Assay (MTS) 
Promega WI, USA 




cOmplete, mini protease inhibitor cocktail 
tablet 
Roche Germany 
Diethylpyrocarbonate (DEPC)  Sigma Aldrich MO,USA 
Dimethyl sulfoxide (DMSO) Sigma Aldrich MO,USA 
Dual-Luciferase Reporter Assay System Promega WI, USA 
Dulbucco’s Modified Eagle’s Medium 
(DMEM) 




Fetal Bovine Serum (FBS) Hyclone Laboratories Logan, UT 
Fugene 6  Roche Germany 
GelRed™ Nucleic Acid gel stain  Biotium  CA, USA 
Glacial Acetic Acid Merck 
Darmstadt, 
Germany 
Glycine Bio-Rad CA,USA 







Kanamycin Sigma Aldrich MO,USA 
Lipofectamine○R  2000 Invitrogen CA,USA 
Lipofectamine○R  RNAiMAX Invitrogen CA, USA 
Luciferase Assay System (Dual) Promega WI,USA 
Methanol Sigma Aldrich MO,USA 
Murine Reverse Transcriptase, MMLV Promega WI,USA 












Nuclear Extract Kit Active Motif CA, USA 
Paraformaldehyde Sigma Aldrich MO,USA 
Penicillin/Streptomycin PAA Laboratories Austria 
Phophatase Inhibitor Cocktails 1 and 2 Sigma Aldrich MO,USA 
Pierce® BCA Protein Assay kit ThermoFisher Scientific IL, USA 
Precision Dual Colour Standard Protein 
Marker 
Bio-Rad CA,USA 
Prolong Gold Antifade Reagent Invitrogen CA,USA 
Protein G Sepharose Breads  Roche Germany 
Proteosome-GloTM Chymotrypsin-like, 
Trypsin-like and Caspase-like Cell Based 
Assay 
Promega WI, USA 
PVDF Membrane Bio-Rad CA,USA 
Qiagen plasmid DNA purification Kit (maxi 
and miniprep kit) 
Qiagen GmBH Hilden, Germany 
Qiagen RNasey RNA extraction Kit (RNA 
miniprep kit) 
Qiagen GmBH Hilden, Germany 
Recombinant human TGF-β1 R & D Systems Abingdon, UK 
RPMI 1640 Life Technologies 
Gaithersburg, 
MD 
Skim Milk powder Sigma Aldrich MO,USA 
Sodium Dodecyl Sulfate (SDS) Bio-Rad CA,USA 
Sodium Fluoride Sigma Aldrich MO,USA 
TaqMan Gene Expression Assay (Real time 
PCR) 
ABI systems CA,USA 
Tetramethylethylenediamine (TEMED) Bio-Rad CA,USA 
Tris-Base Bio-Rad CA,USA 
Trizol Sigma Aldrich CA,USA 
Tween 20 Sigma Aldrich MO,USA 
   
Table 2.1. List of chemicals, reagents, and kits 
2.1.2. Antibodies 
2.1.2.1 Antibodies for Western Blotting 













Overnight at 40C 
ATF6 Santa Cruz 
Biotechnologies 
Goat Polyclonal 1:1000 Overnight at 40C 




1:1000 Overnight at 40C 




1:1000 Overnight at 40C 




1:2000 Overnight at 40C 
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1:1000 Overnight at 40C 




1:1000 Overnight at 40C 
HDAC1 Santa Cruz 
Biotechnologies 
Goat Polyclonal 1:500 Overnight at 40C 




1:5000 Overnight at 40C 
Flag Sigma Aldrich Mouse 
Monoclonal 
1:10000 Overnight at 40C 
GRP 78 Santa Cruz 
Biotechnologies 
Goat Polyclonal 1:1000 Overnight at 40C 




1:1000 Overnight at 40C 
N-CoR Santa Cruz 
Biotechnologies 
Goat Polyclonal 1:500 Overnight at 40C 




1:500 Overnight at 40C 




1:250 Overnight at 40C 




1:2000 Overnight at 40C 




1:1000 Overnight at 40C 




1:1000 Overnight at 40C 




1:1000 Overnight at 40C 




1:1000 Overnight at 40C 




1:1000 Overnight at 40C 




1:2000 Overnight at 40C 




1:1000 Overnight at 40C 




1:1000 Overnight at 40C 




1:1000 Overnight at 40C 
Runx1 Active Motif Rabbit 
Polyclonal 
1:1000 Overnight at 40C 




1:1000 Overnight at 40C 




1:1000 Overnight at 40C 




1:1000 Overnight at 40C 




1:1000 Overnight at 40C 




1:1000 Overnight at 40C 




1:1000 Overnight at 40C 




Target Company Dilution Incubation Period 
 






1h, room temperature 
HRP Goat Anti-Mouse Zymed Laboratories 1:10000 1h, room temperature 
HRP Rabbit Anti-Goat Zymed Laboratories 1:10000 1h, room temperature 
Table 2.3. List of secondary antibodies 
2.1.2.2 Antibodies for Immunostaining  
Target Company Reactivity Dilution Incubation Period 















N-CoR Santa Cruz 
Biotechnologies 
Goat Polyclonal 1:100 2h, room 
temperature 
PDI Santa Cruz 
Biotechnologies 
Rabbit Polyclonal 1:100 2h, room 
temperature 
Table 2.4. List of primary antibodies used in immunofluorescent staining 
Description Company Dilution Incubation Conditions 
    
Alexa Flour Chicken Anti-
Goat 488 
Invitrogen 1:200 1hr, Room Temperature 
Alexa Flour Chicken Anti-
Goat 594 
Invitrogen 1:200 1hr, Room Temperature 
Alexa Flour Chicken Anti-
Mouse 488 
Invitrogen 1:200 1hr, Room Temperature 
Alexa Flour Chicken Anti-
Mouse 594 
Invitrogen 1:200 1hr, Room Temperature 
Alexa Flour Chicken Anti-
Rabbit 488 
Invitrogen 1:200 1hr, Room Temperature 
Alexa Flour Chicken Anti-
Rabbit 594 
Invitrogen 1:200 1hr, Room Temperature 
Table 2.5. List of secondary antibodies used in immunofluorescent staining 
2.1.3 Primer Sequences 
2.1.3.1 Semi-quantitative RT-PCR primers 














 Reverse: TTACATGTCTCGATCCCACT   
GAPDH Forward: TGATGACATCAAGAAGGTGG 60 30 









SMAD2 Forward: GTTCCTGCCTTTGCTGAGAC 60 30 
 Reverse: TCTCTTTGCCAGGAATGCTT   
SMAD3 Forward: TGCTGGTGACTGGATAGCAG 60 30 
 Reverse: CTCCTTGGAAGGTGCTGAAG   
TGFβ1 Forward: ACCTGCCACAGATCCCCTAT 62 30 
 Reverse: CTCCCGGCAAAAGGTAGGAG   
TGFβ2 Forward: TCTTCCCCTCCGAAAATGCC 62 30 
 Reverse: ATCGAAGGAGAGCCATTCGC   
TGFβ3 Forward: CGAGCAGAATTCCGGGTCTT 62 30 
 Reverse: ATCAAAGGACAGCCACTCGG   
TGFBRI Forward: CATTTTTCCCAAGTGCCAGT 60 30 
 Reverse: ACACCCCTAAGCATGTGGAG   
TGFBRII Forward: CCATGTCTCACAGCCAGCTA 60 30 
 Reverse: CCAGGAGAAATAAGGGCACA   
Table 2.6. List of semi-quantitative RT-PCR primers 
2.1.3.2 Real-time PCR Primer Assays (Taqman) 






NCoR Hs01094540_m1   
p21 Hs00355782_m1   
PAI-1 Hs01126606_m1   
Table 2.7. List of Taqman Assays used in Real-Time PCR analysis 
2.1.3.3 siRNA sequences 






NCoR AATGCTACTTCTCGAGGAAACA   
Smad2 (1) GCCACAUGUUAUAUAUUGCCGAUUA   
Smad2 (2) UAAUCGGCAAUAUAUAACAUGUGGC   
Smad2 (3) UCUGGAUGACUAUACUCACUCCAUU   
Smad3 CCACCAGGAUGCAACCUGAAGAUCU   
 AGAUCUUCAGGUUGCAUCCUGGUGG   
 AGGACGAGGUCUGCGUGAAUCCCUA   
TGFBRI GCAUCUCACUCAUGUUGAUGGUCU   
 UAGACCAUCAACAUGAGUGAGAUG   
 GCCAAAUGAAGAGGACCCUUCAUUA   
TGFBRII UCCUGACUUGUUGCUAGUCAUAUUU   
 AAAUAUGACUAGCAACAAGUCAGGA   
 UCAUCUUCUACUGCUACCGCGUUAA   
Table 2.8. List of siRNA sequences used in siRNA mediated knockdown 
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2.1.4 Gastric Cancer Tissue 
2.1.4.1 Human Samples 
Gastric cancer tissues were obtained from 10 patients diagnosed with stomach 
carcinoma. Tissues were collected from the tissue repository of National 
University Hospital (Singapore) and the use of these samples has been 
approved by the NUS Institutional Review Board (IRB). Paired tissues were 
obtained from each patient, one from the tumour region of the resected 
stomach and the other matching control from adjacent non-tumour (normal) 
region.  
2.1.4.2 Tissue Microarray 
The stomach cancer tissue array from US Biomax (ST811) was selected for 
immunohistochemistry (IHC) studies. It consists of 80 cores - 70 cases of 
stomach tumor and 10 normal tissue. 
2.1.5 Plasmids 
2.1.5.1 pACT-NCoR-FLAG 
The pACT vector (Promega, USA) is a non-viral mammalian expression 
vector containing CMV promoter and carries the ampicillin bacterial 
resistance gene. pACT-NCoR-FLAG consists of 2 tandem repeats of Flag 
sequence, linked in frame to the C-terminus of mouse N-CoR sequence and 
cloned into the vector at Nco1 and Xba1 sites. 
2.1.5.2 IgCα promoter construct 
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The TGF-β-responsive element (TβRE) promoter reporter construct, 
generously provided by Dr. Ko Tun Kiat (Cancer Science Institute, 
Singapore), was derived from the mouse germline Ig Cα promoter and 
contained three tandemly repeated wild-type TβREs of the Ig Cα promoter 
fused to a heterologous c-Fos and luciferase reporters. All of the polymerase 
chain reaction products were sequenced 69. 
2.1.5.3 pACT-RUNX1/RUNX2/RUNX3 
pACT-RUNX plasmids were kindly provided by Professor Yoshiaki Ito 
(National University of Singapore), and were constructed as previously 
described [68]. 
2.1.6 Cell Lines 
2.1.6.1 Human Gastric Cancer Cell Lines 
SNU-5 and SNU-16 cell lines were generous gifts from Dr Ayumi Yamada. 
All other human gastric carcinoma cell lines (SNU-1, SNU-620, SNU-719, 
SCH, MKN1, MKN7, MKN28, MKN74, TMK1, NUGC3 and AZ52) were 
kindly provided by A/Prof Richie Soong (Cancer Science Institute, National 
University of Singapore, Singapore).  
2.1.6.2 Non-gastric Cancer Cell Lines 
HEK 293T (Human Embryonic Kidney) cells were purchased from the 
American Type Culture Collection, USA. P19 murine embryonal carcinoma 
cells were kindly provided by A/Prof Motomi Osato (Cancer Science Institute, 
Singapore). HFE-145, an immortalized human normal gastric epithelial cell 
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Artemisinin derivatives (GC001, GC003, GC006, GC008, GC009, GC010, 
and GC011) were synthesized and generously provided by our collaborator, 
Professor Richard K. Haynes (Hong Kong Science and Technology 
University, Hong Kong). The derivatives used in this study were prepared 
according to the literature methods 103,179. The derivatives were reconstituted 
in dimethyl sulfoxide (DMSO) to a stock concentration of 25 mM and kept in 




Figure 2.1. Chemical structures of artemisinin derivatives used 
2.1.7.2 Bortezomib 
Bortezomib (LC Laboratories, Woburn, MA), a specific and reversible 
proteasome inhibitor, was reconstituted in DMSO to a stock concentration of 
10 mM and kept in aliquots at -20°C. 
 
Figure 2.2 Chemical structure of Bortezomib 
2.1.7.3 LY2157299 
LY2157299 (Selleck Chemicals, US) is a selective small molecule 
transforming growth factor beta receptor kinase inhibitor with IC50 of 86 nM 
and 2 nM for TβRI and TβRII respectively. LY2157299 was reconstituted in 
DMSO to a stock concentration of 20 mM, and subsequently kept at -20°C. 
  




2.1.7.4 Recombinant human TGFβ1 
Recombinant Human TGF-β1 (R&D Systems, Abingdon, UK) was 
reconstituted in sterile 4 mM HCl containing 1 mg/mL bovine serum albumin 



















2.2.1 Cell Culture Treatment 
2.2.1.1 Maintenance of Cell Lines 
All gastric cancer cell lines and HFE-145 cell line were maintained in RPMI 
1640 enriched with 10% heat-inactivated fetal bovine serum (FBS), in a 
humidified atmosphere of 5% CO2 at 37°C. 293T and P19 cells were cultured 
in DMEM supplemented with 10% heat-inactivated FBS in a humidified 
atmosphere of 5% CO2 at 37°C. For subculturing, cells were either directly 
split into new flasks containing fresh media at an appropriate split ratio, or if 
adherent, trypsinized with 0.05% trypsin-EDTA first, and then resuspended 
with culture media and split into new flasks containing fresh media. Cells 
were typically passaged every 2-3 days, before reaching confluency. 
2.2.1.2 Cryopreservation of Cell Lines 
For cryopreservation of cells, suspension cells were centrifuged at 200 g for 5 
minutes, while adherent cells were trypsinized with 0.05% trypsin-EDTA 
prior to centrifugation, and cell pellets were resuspended in sterile-filtered 
freezing medium [90% (v/v) of heat-inactivated FBS, 10% (v/v) DMSO] at a 
cell density not exceeding 1 X 106 cells/mL. 1 mL cell suspensions were then 
aliquoted into sterile cryovials and placed into cryofreezing containers. The 
cells were then gradually frozen at a rate of 1°C/min in a -80°C freezer 





2.2.1.3 Thawing of Cells 
Cryovials containing the cells were removed from liquid nitrogen storage and 
immediately transferred to a 37°C water bath to be thawed rapidly. An 
appropriate volume of pre-warmed culture media were added to the cell 
suspensions and centrifuged at 200 g for 5 min to remove traces of DMSO. 
The cells were then resuspended in fresh culture media and transferred to new 
flasks and subsequently incubated in a humidified atmosphere of 5% CO2 at 
37°C. 
2.2.1.4 Treatment of cells with drugs 
Cells were seeded at a density of 2-4 X 105 cells/mL on sterile tissue culture 
plates, depending on the treatment and doubling time of the cells. The drugs 
(GC011, Bortezomib, TGF-β or LY2157299) and control vehicles were then 
diluted in complete growth medium to the required concentrations and added 
to the cells at the appropriate time-points. For adherent cell lines, cells were 
allowed to grow and attach overnight in a humidified atmosphere of 5% CO2 
at 37°C prior to treatment. 
2.2.1.5 Transfection of Cells 
2.2.1.5.1 Transfection of 293T cells using Fugene 6  
Transfection of 293T cells using Fugene 6® tranfection reagent was carried 
out according to the manufacturer’s protocol. Cells were seeded at a density of 
2 X 105 cells/mL on a 10-cm tissue culture plate and incubated overnight at 
37°C and 5% CO2. Approximately 18-22 hours after seeding, transfection was 
carried out. Briefly, 18 µl of Fugene 6 was diluted in 582 µL of serum-free 
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media and incubated for 5 minutes at room temperature. 6 µg of total DNA 
was then added to the diluted Fugene 6 and allowed to incubate for 15 minutes 
at room temperature. The DNA-Fugene 6 complex was then added dropwise 
to each plate of cells. Cells were assayed for analysis 48 hours post-
transfection. 
2.2.1.5.2 Transfection of P19 cells and SNU16 cells using Lipofectamine 2000  
Cells were seeded at a density of 1 X 105 cells/mL (for P19) or 2 X 105 
cells/mL (for SNU16) in serum-free DMEM in a 6-well plate. For each well of 
cells, 100 pmol of target and mock siRNA (refer to Table 8), or 2 µg of total 
DNA was diluted in OptiMEM® medium I to a total volume of 250 µl. 5 µl of 
Lipofectamine 2000 was diluted in 250 µl of OptiMEM® I medium and 
incubated for 5 minutes at room temperature. The diluted siRNAs and 
Lipofectamine 2000 was then combined and incubated at room temperature 
for 20 minutes to allow siRNA-Lipofectamine 2000 complexes to form. The 
complexes were then added to the cells and incubated for 4 hours at 37°C and 
5% CO2 before replacing the media with DMEM supplemented with 10 % 
FBS. Cells were then assayed 48 hours post-transfection. 
2.2.2 Analysis of Proteins 
2.2.2.1 Total Protein Extraction from cells 
Two lysis buffers were used to prepare cell lysates. Cells were firstly 
trypsinized (for adherent cells only) and cell pellets were then collected by 
centrifuging at 200g for 5mins at 4°C. The resulting pellets were rinsed twice 
with ice-cold 1X PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM NaH2PO4, 1.4 
mM KH2PO4, pH7.4). The cells were then lysed using either 1 X SDS sample 
55 
 
buffer [250mM Tris-HCl (pH6.8), 40% glycerol, 9.2% SDS, 0.01% 
bromophenol blue, 20% β-mercaptoethanol] or CelLyticTM M reagent 
(supplemented with protease inhibitor cocktail tablet, 1 mM AEBSF, 1% (v/v) 
Phosphatase Inhibitor Cocktail 1 & 2). For cells lysed with 1 X SDS sample 
buffer, cells were lysed with 5 X pellet volume of the buffer. Cells were then 
sonicated twice at 5W for 10 seconds on ice (Branson Sonifier 150). The cell 
lysates were then heat inactivated at 50°C for 10 mins and subsequently stored 
at -80°C until further use. For cells lysed with the CelLytic M Reagent, 
appropriate volumes of the reagent were added to each pellet and cell lysates 
were sonicated at 5W on ice for 10 seconds twice. Lysates were then 
centrifuged at maximum speed for 20 minutes at 4°C to remove cellular 
debris, and supernatants were collected. Protein concentration was determined 
using BCA protein assay and 4 X SDS sample buffer was added to the lysates 
to a final 1 X SDS concentration. Lysates were then heat inactivated at 50°C 
for 10 minutes and subsequently stored at -80°C until further use. 
2.2.2.2 Nuclear and Cytoplasmic Extraction of Protein from cells 
Nuclear and cytoplasmic extracts of cells were prepared using Active Motif 
Nuclear Extract kit, according to the recommended protocol. Growth medium 
was first removed from cells and cells washed with PBS/phosphatase 
inhibitors. Cells were then gently scraped in PBS/phosphatase inhibitors and 
centrifuged at 500 rpm for 5 minutes. The cell pellets were then resuspended 
in 1 X Hypotonic Buffer and incubated on ice for 5 minutes. Detergent was 
added and suspension was vortexed to mix. Centrifugation was then 
performed at 14 000 x g for 30 seconds at 4°C and upernatants (cytoplasmic 
fraction) collected. Nuclear pellets were then resuspended in Complete Lysis 
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Buffer and vortexed for 10 seconds at the highest setting, followed by 
incubation on ice for 30 minutes on a rocking platform set at 150 rpm. 
Suspensions were then vortexed for 30 seconds at the highest setting, 
centrifuged for 10 minutes at 14 000 x g at 4°C and supernatants (nuclear 
fraction) collected. All supernatants were then sonicated twice at 5W for 10 
seconds on ice and protein concentration was determined. 4 X SDS sample 
buffer was added to a final 1 X SDS concentration. Lysates were then heat 
inactivated at 50°C for 10 minutes and subsequently stored at -80°C until 
further use. 
2.2.2.3 Protein Solubility Assay 
Cells were pelleted at 300 g for 5 min and then resuspended in cell lysis buffer 
[50 mM Tris-HCl (pH 8.8), 100 mM NaCl, 5 mM MgCl2, 0.5% NP-40, 1 
µg/ml pepstatin, 1 µg/ml aprotinin, 200 µM AEBSF] before rotation at 4°C for 
45 min.  The soluble fraction (supernatant) was then separated from the 
insoluble fraction (pellet) by centrifugation at 20000 g for 10 minutes. The 
pellet was then resuspended in pellet buffer [20 mM Tris-HCl (pH 8.0), 15 
mM MgCl2, 1 µg/ml pepstatin, 1 µg/ml aprotinin, 200 µM AEBSF] and 
treated with DNase I for 30 min at 37°C. 4 X SDS sample buffer was then 
added to the fractions to a final 1 X concentration and subsequently heat-
inactivated at 50°C for 10 minutes. Proteins were resolved with SDS-PAGE 
and transferred to PVDF membranes for western blotting. Coomassie blue 






Cells were collected by centrifugation at 200 g for 5 minutes, and washed in 
cold 1 X PBS. Cells were then lysed in IP buffer (20mM Tris pH7.4, 300mM 
NaCl, 0.5% NP-40, 1mM EDTA, 200μM AEBSF, 1 tablet/50ml cOmplete 
protease inhibitor cocktail, 1mM NaF, 20mM β-Glycerolphosphate, 10ul/ml 
Phosphatase Inhibitor Cocktail I, 10μl/ml Phosphatase Inhibitor Cocktail 2) at 
an appropriate volume (500 µl for every 10-cm plate). Lysates were sonicated 
twice at 5W for 10 seconds on ice and then centrifuged at 850 g for 5 minutes 
at 4°C. 100 µl of the lysate was heat inactivated at 50°C for 10 minutes and 
subsequently stored at -80°C to be analysed for loading input. 
Immunoprecipation was then carried out on the remaining supernatants with 
10 µg of anti-Flag, anti-N-CoR antibody or normal goat IgG by rotation for 
2.5 hours at 4°C. Protein G sepharose beads which were prepared by washing 
in IP buffer and resuspending in IP buffer were then added to each sample and 
lysates were rotated for another 1.5 hours. The bound protein-Protein G were 
then collected by centrifugation at 850 g for 5 minutes and washed 4 times 
with IP buffer. The bound protein was then released by the addition of 2 X 
SDS sample buffer to a final concentration of 1 X SDS. The samples were 
again centrifuged at 850 g for 5 minutes to remove protein G beads. The 
remaining supernatants were then heat inactivated at 50°C for 10 minutes and 
stored at -80°C until further analysis. 
2.2.2.5 Protein Quantification 
Protein quantification was carried out using Pierce® BCA Protein Assay kit, 
according to manufacturer’s instructions. 200µl of the working reagent was 
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added to 5 µl of BSA standards or unknown samples in a 96-well plate and 
incubated at 37°C for 30 minutes. Absorbance was then measured at 562 nm 
on a plate reader and concentration was calculated against the BSA standard 
curve. 
2.2.2.6 SDS PAGE 
Cell lysates were resolved using the SDS-PAGE Bio-Rad Mini-Protean II 
system. Denaturing polyacrylamide gels were cast using a mini-Protean gel 
caster. Resolving gels (refer to Table 10) were prepared and allowed to set for 
30 minutes. Stacking gels (refer to Table 10) were then prepared and allowed 
to set for another 30 minutes before being assembled into the electrophoresis 
chamber. The inner and outer chambers of the unit were then filled with ice-
cold 1 X SDS-PAGE running buffer (25mM Tris-Base, 192 mM glycine, 0.1% 
SDS w/v). Protein samples were then loaded into the wells and electrophoresis 
was carried out at 4°C at a constant current of 10 mA through each stacking 
gel and increased to 20 mA through each resolving gel. After electrophoresis, 
the gels were either subjected to Western Blotting or stained with Coomassie 
Blue for 30 minutes at room temperature for visualization of total protein.  
 Resolving Gel  
Stacking 
Gel 


















2.0 2.7 3.3 4.0 5.0 1.71 
1.5 M Tris-HCl, 
pH 8.8 (ml) 
2.5 2.5 2.5 2.5 2.5 - 
0.5 M Tris-HCl, 
pH 6.8 (ml) 




0.1 0.1 0.1 0.1 0.1 0.1 






TEMED (µl) 8 6 4 4 4 10 
Total volume 
(ml) 
10 10 10 10 10 10 
Table 2.9. Preparation of SDS-PAGE denaturing gels 
2.2.2.7 Western Blotting 
After electrophoresis, resolved proteins were transferred onto pre-wet PVDF 
membranes using the wet transelectroblotting system (Bio-Rad, US) in ice- 
cold 1 X transfer buffer (48 mM Tris-base, 37 mM Glycine, 0.037% SDS w/v, 
10% MeOH v/v) at a constant current of 75 mA for 2 hours at 4°C. The 
membrane was then blocked with 5% skimmed milk powder in PBS-T (1 X 
PBS, 0.01% Tween-20) at room temperature for 1 hour. The membrane was 
then incubated with the primary antibody at the appropriate dilutions in 5% 
milk/PBS-T (refer to Table 2) overnight at 4°C. Membranes were then washed 
4 X 5 minutes in PBS-T before incubation with secondary antibodies in 2.5% 
milk/PBS-T for 1 hour at room temperature (refer to Table 3). Membranes 
were again washed 6 X 5 minutes in PBS-T before detection with enhanced 
chemiluminescent reagents and exposure to Fuji X-Ray film. After 
immunodetection, membranes were stripped of the bound antibodies using 
stripping buffer (200 mM glycine, 1% SDS, pH 2.5) for 30 minutes at room 
temperature, blocked in 5% mik/PBS-T and reprobed with other antibodies if 
needed.  
2.2.3 Cell Based Assays 
2.2.3.1 Cell Proliferation Assay 
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2.2.3.1.1 Cell Proliferation kit I [3-(4,5-dimetylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT)] 
The cell proliferation assay was carried out according to the manufacturer’s 
protocol. Cells were seeded into 96-well plates at 8 X 103 cells per well in 
100μl culture medium containing different concentrations of the drug tested. 
Cells were then incubated at 37°C and 5% CO2 for the durations stated. MTT 
substrate was then added to the cells and incubated at 37°C for 4 hours, 
followed by the addition of the lysis reagent for 18 hours at 37°C. The 
spectrophotometric absorbance was measured using a microplate reader 
(Ultramark, Bio-Rad, Hercules, CA) using a wavelength of 595 nm with a 
reference wavelength of 655 nm.  
2.2.3.1.2 CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS) 
The cell proliferation assay was carried out according to the manufacturer’s 
protocol. Cells were seeded into 96-well plates at 8 X 103 cells per well in 
100μl culture medium containing different concentrations of the drug tested. 
Cells were then incubated at 37°C and 5% CO2 for the durations stated. 10 µl 
of the MTS reagent was added to each well and incubated at 37°C for 3 hours. 
Absorbance was subsequently recorded at 490 nm on a microplate reader 
(Ultramark, Bio-Rad, Hercules, CA). 
2.2.3.2 Immunofluorescent Staining 
For suspension cells, 100-200 µl of cells were cytospun onto Shandon 
cytoslides® at 1000 rpm for 5 minutes in a cytospin centrifuge. For attached 
cells, cells were seeded onto cover slips placed in a 6-well tissue culture plate 
and allowed to attach overnight at 37°C and 5% CO2. Cells were then fixed 
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with 4% paraformaldehyde at 37°C, washed with 1 X PBS, and permeabilized 
with 0.2% Triton X-100 in 1 X PBS for 5 minutes on ice. After washing a 
further three times in 1 X PBS, cells were blocked with 5% BSA/PBS for 30 
minutes. Cells were then stained with primary antibody (refer to Table 4) at 
1:100 dilution in 5% BSA/PBS for 2 hours, washed with 1 X PBS, and 
incubated in the dark with fluorescence-labelled secondary antibodies (refer to 
Table 5) at 1:200 dilution in 2.5% BSA/PBS for 1 hour. After washing three 
times in 1 X PBS, the cell nuclei were then counterstained with 150 nM 4’,6-
diamidino-2-phenylindole (DAPI) in 5% BSA/PBS for 5 minutes. Cells were 
then mounted with SlowFade® Gold antifade reagent and coverslips were 
sealed. Images were subsequently visualized and captured using AxioPlan 2 
imaging fluorescence microscope (Carl Zeiss). 
2.2.3.3 Immunohistochemistry staining 
Immunohistochemical staining of tissue microarray was done using the goat 
ImmunoCruz™ Staining System, according to manufacturer’s protocol. The 
tissue microarray slides were firstly baked at 60°C for 10 min to melt the wax 
and improve adhesion before staining. Heat treatment was then applied for 
antigen retrieval by soaking slides in 10 mM sodium citrate buffer, pH 6.0 at 
95°C for 10 minutes. Slides were then allowed to cool in buffer for 20 
minutes, before washing in deionized H2O three times for 2 minutes each. 
Excess liquid was then removed carefully from the sides of the slides between 
each wash. Endogenous peroxidise activity was quenched with 1-3 drops of 
peroxidase block, followed by rinsing in PBS for 2 minutes. The slides were 
then incubated in serum block for 20 minutes, followed by incubation with 5 
µg goat anti-N-CoR antibody for 2 hours at room temperature. The slides were 
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then rinsed twice in PBS for 2 minutes each. Next, the slides were incubated 
for 30 minutes in 1-3 drops of biotinylated secondary antibody, and again 
rinsed in PBS twice for 2 minutes each. The slides were then incubated in 1-3 
drops of HRP-streptavidin complex for 30 minutes and rinsed twice in PBS for 
2 minutes each. The slides were then further incubated with HRP Substrate 
chromogen solution for 5 minutes and rinsed in deionized H2O for 2 minutes. 
Slides were counterstained with Mayer’s hematoxylin for 10 seconds and 
immediately washed several times with deionized H2O. Slides were then 
finally mounted with SlowFade® Gold antifade reagent and covered with 
coverslips. Images were subsequently visualized and captured using AxioPlan 
2 imaging fluorescence microscope (Carl Zeiss). 
2.2.3.4 Detection of Apoptosis by Flow Cytometry  
Detection of phosphatidylserine (PS) on the outer leaflet of apoptotic cells was 
performed using Annexin V-FITC Apoptosis Detection Kit according to the 
manufacturer’s recommendations. Briefly, cells were collected and pellets 
were washed once with ice-cold 1 X PBS. Cell pellets were then resuspended 
in 1 X Annexin V binding buffer at a concentration of 1 X 106 cells/ml.  5 µl 
of FITC conjugated anti-Annexin V antibody and Propidium Iodide were 
added to 100 µl of the cell suspension. Mixture was then vortexed gently and 
incubated for 15 minutes in the dark at room temperature. 400 µl of 1 X 
Binding Buffer was then added to each sample and cells were analysed by 
flow cytometry within an hour. Flow cytometry was performed using 




2.2.3.5 In vivo ubiquitination assay 
293T cells were transfected with 2 μg of pact-N-CoR-FLAG expression 
vector, 2 μg of pcDNA3-Myc-Ub expression vector and 2 μg of either pact-
RUNX1, pact-RUNX3 or empty actin vector. Thirty hours after transfection, 
the cells were treated with 10 μM MG132 for another 12 hours. 
Immunoprecipitation was then carried out as per Section 2.2.2.3. 
2.2.4 Gene Expression Analysis 
2.2.4.1 RNA extraction 
Purification of total RNA was carried out using RNeasy® Mini Kit protocol. 
Up to 1 x 107 cells, depending on the cell line, were disrupted in Buffer RLT, 
a highly denaturing guanidine-thiocyanate containing buffer which inactivates 
RNases (0.01% β-mercaptoethanol was added before use) by homogenizing 
with needle and syringe. 1 volume of 70% ethanol was then added to the 
homogenized lysates before being applied to the RNeasy Mini spin columns 
for binding of RNA to the resin. The RNA-resin was then washed with DNase 
I containing buffer RW1 to remove DNA and protein contaminants. Purified 
RNA was finally eluted in 30 µl of DEPC treated water and its concentration 
determined using Nanodrop Spectrophotometer ND-1000 (Thermo Fisher 
Scientific, Lafayette, CO, USA). All binding, washing, and elution steps were 
performed by centrifugation at 10,000 rpm at room temperature. 
2.2.4.2 Reverse transcription 
3 µg of purified RNA was used for cDNA synthesis using RT-PCR System 




was added to a final volume of 21 µl and incubated at 65°C for 15 minutes 
before immediately quenching on ice. 10 μl of 5 X RT buffer, 1 μl of 25 mM 
dNTPs, 0.5 μl of RNasin Inhibitor, 1 μl of murine reverse transcriptase and 
sterile water were then added to each sample. Samples were further incubated 
at 42°C for 1 hour to generate cDNA. cDNA synthesis was completed after 
inactivation of transcriptase by incubation at 95°C for 5 minutes. cDNAs were 
then stored at –20°C until subjected to semi-quantitative PCR or real-time 
PCR analysis.  
2.2.4.3 Semi-quantitative Polymerase Chain Reaction (PCR) 
A PCR mastermix (1.5 mM of MgCl2, 1 X Green GoTaq® Reaction Buffer, 
0.2 mM of each dNTP, 1 μM of each downstream and upstream primer, 1.25 
units of GoTaq® DNA Polymerase and nuclease-free water topped up to 49 µl 
per reaction) was prepared and added to 1µl of cDNA template diluted 1:10 in 
nuclease-free water for a total reaction volume of 50 µl per sample. PCR 
amplification was carried out under conditions as stated in Table 2.10 using 
Thermal Cycler GeneAmp®PCR System 9600 (Applied Biosystems, CA, 
USA). Depending on the primers, the annealing temperature and number of 
cycles were optimized accordingly (Refer to Table 2.6). 







2. Denaturation 94 30s 
3. Annealing * 30s 
4. Extension/Elongation 72 30s 
5. Final Elongation 72 7 mins 
6. Final Hold 4  
Table 2.10. PCR amplification steps.  




2.2.4.4 DNA agarose gel electrophoresis 
Agarose gel electrophoresis was carried out to analyse PCR products. 1-2 % 
w/v agarose gel (1-2 g of electrophoretic grade agarose powder in 100 ml 1 X 
TAE buffer [40 mM Tris-acetate (pH 7.8), 1 mM EDTA]) stained with 
GelRed™ Nucleic Acid gel stain (Biotium) at a 1:10000 dilution were 
prepared. PCR products were then resolved by electrophoresis in 1 X TAE 
buffer at 100V for 25 minutes. Gene expression levels were then visualized 
under trans UV on the Gel Doc System (Bio-Rad, CA,USA). 
2.2.4.5 Real-time PCR 
Real time PCR analysis was carried out using the Taqman® Gene Expression 
Assay System (Applied Biosystems, CA,USA) and Ct values were recorded 
using the ABI Prism 7300 Real Time PCR system (Applied Biosystems, CA, 
USA).  The PCR reaction and PCR conditions used are as listed in Table 2.11 
and 2.12 respectively. 
Component Volume used per reaction (μl) 
 
2 X Taqman Universal PCR master mix 
 
12.5 
20 X Primer Mix 1.25 
Nuclease-Free Water 10.25 
cDNA (diluted 1:3 in nuclease-free water) 1 
Total Volume 25 
Table 2.11. Real Time PCR Reaction using the Taqman® Gene Expression Assay 
System. 
 
Step Temperature (0C) 










Denaturing 94 15 s 
40 
Annealing  60 1 min 
Elongation 60 10 min 1 
Table 2.12. PCR conditions using the ABI Prism 7300 system. 
66 
 
Data was analysed using the ddcT study protocol, in which the comparative Ct 
method was employed (∆∆Ct = ∆Ct,sample - ∆Ct,reference). Untreated samples 
were used as reference samples and Ct values of both reference and target 
samples were normalized to that of the endogenous housekeeping gene HPRT. 
Expression levels in the reference sample for all genes were set to 0.  
2.2.5 Proteosome Activity Assay  
Measurement of proteosomal activity in MKN74 cells treated with 
Bortezomib was carried out using Proteosome Glo™ Assay system, which 
measures three proteolytic activities associated with the proteasome - 
chymotrypsin-like, trypsin-like, and caspase-like. components. The 
luminogenic substrates provided for the chymotrypsin-like, trypsin-like, and 
caspase-like activities are Suc-LLVY- aminoluciferin, Z-LRR-aminoluciferin, 
and Z-nLPnLD-aminoluciferin, respectively. Substrate cleavage generates a 
“glow-type” luminescent signal produced by the luciferase reaction. Briefly, 
cells were trypsinized, washed 2 X with complete medium, and resuspended in 
complete medium adjusted to the desired density. 2000 cells were seeded into 
each well in 25 µl of complete medium and returned to the incubator until 
measurement was to be carried out. The Proteosome-Glo™ Cell-Based 
reagents and plate containing cells were then allowed to equilibrate to room 
temperature. 25 µl of each of the Proteosome-Glo™ Cell-Based reagent was 
added to well. Samples were then shaken at 700 rpm for 2 minutes and 
incubated at room temperature for 10 minutes. Luminescence was then 




2.2.6 Luciferase Reporter Assay 
P19 cells were transfected with the Ig Cα promoter reporter construct and 
target DNA using Lipofectamine 2000 (Invitrogen, Lidinggo, Sweden), 
according to the protocol provided by the manufacturer (refer to 2.2.3.2). The 
cells were harvested 48 hours post-transfection, and Firefly and Renilla 
luciferase activities were assayed with the Dual-Luciferase Reporter Assay 
System (Promega, Madison, WI, USA), according to manufacturer’s 
instructions. In brief, growth medium was removed from cells and cells were 
then washed briefly with 1 X PBS. 500 µL of 1 X PLB was added to each well 
and plates were then placed on a rocking platform for 15 minutes at room 
temperature. Lysates were then transferred into microcentrifuge tubes and 
cleared of cellular debris by centrifugation at high speed for 30 seconds at 
4°C. 20 µl of each of the PLB lysates were then transferred into the 
luminometer tubes containing 100 µl of LAR II and mixed by pipetting up and 
down 2-3 times. The firefly luciferase activity was then recorded. 100 µl of 
Stop & Glo® Reagent was then added to each tube, and vortexed briefly to 
mix. The Renilla luciferase activity was then recorded. Firefly luciferase 





















3.1 GC011, an artemisinin derivative, selectively attenuates growth of 
TGF-β-sensitive gastric cancer cells by inhibiting N-CoR-induced 
repression of TGF-β apoptotic signaling pathway. 
3.1.1 Artemisinin derivatives demonstrate differential cytotoxicity on human 
gastric cancer cell lines SNU5 and SNU16.  
It has been reported that artemisinin and its derivatives demonstrate 
differential anti-malarial activities.103,179 In recent years, artemisinin 
derivatives have also emerged as a novel class of anti-cancer agent with 
pleiotropic anti-cancer responses in many types of cancer cells. Despite the 
mounting evidence of its antineoplastic properties, only one study had tested 
the artemisinin compounds on gastric cancer cells.180 Furthermore, while 
artemisinins have been shown to affect various cellular molecular pathways 
involved in several hallmarks of malignancy, none has yet been reported in 
gastric cancer cells. Due to this lack of evidence, this present study aims to 
investigate the anti-tumor effects of artemisinins in gastric cancer cells and 
elucidate the molecular cellular pathway involved. 
Firstly, to investigate if artemisinin derivatives differ in their anti-tumor 
activities against gastric cancer cells, we performed a small-scale screening of 
a panel of seven 10-aminoartemisinin compounds (Fig. 2.1 & 3.1) against 
human gastric cancer cell lines SNU16 and SNU5, the prototypic TGF-β 
sensitive and resistant gastric cancer cell lines respectively, using a wide range 
of drug concentrations and incubation periods. MTT assay was performed to 
compare the effects of these derivatives on the cell viability of these cell lines. 
The TGF-β sensitive cell line SNU16 displayed differential cytotoxic profiles 
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when treated with each artemisinin derivative. Out of the seven derivatives 
tested, GC003, GC008, GC010 and GC011 inhibited the growth of SNU16 
cells in both dose- and time-dependent manner (Fig. 3.2A). These four 
derivatives demonstrated significant growth inhibitory effects, with IC50 
values of 3.8 μM, 3.8 μM, 3.9 μM and 2.1 μM at 96 hours respectively (Fig. 
3.2B). In particular, GC011 was capable of inhibiting approximately 30% cell 
growth even with a low dose of 1 μM at 48 hours. In contrast, all the 
derivatives displayed little or no growth inhibitory effects on the TGF-β 
resistant cell line SNU5, even at 10 μM concentrations and treatment periods 
of up to 96 hours (Fig. 3.3). Artemisinin derivative GC011 (Fig. 3.1) is 
therefore identified as the most potent suppressor of growth of TGF-β 
sensitive gastric cancer cells SNU-16 among this panel of derivatives. 
 
 
Figure 3.1. Artemisinin and its derivatives dihydroartemisinin and artesunate. 
The active pharmacophore is the peroxide bridge that bestows antimalarial activity, 
and the derivatives are now widely used for treatment of malaria. GC011 is a newer 
derivative prepared from dihydroartemisinin that possesses potent antimalarial 
activity in in vitro screens. The pyrimidinylpiperazinyl unit attached to C10 in GC011 
confers enhanced lipophilicity as compared to artemisinin and the derivatives 

























Figure 3.2. Differential effects of artemisinin derivatives on growth of TGF-β 
sensitive gastric cancer cell line, SNU16. (A) Growth of SNU16 cells treated with 
artemisinin derivatives (GC001, GC003, GC006, GC008, GC009, GC010 and 
GC011) in a dose-dependent manner for a total duration of 24h, 48h, 72h or 96h was 
determined by MTT assay. The values plotted in bar graph are average of three 
independent experiments. *p < 0.05 and **p < 0.01, compared with untreated 
controls. (B) IC50 values at 24, 48, 72 and 96 hours were obtained for all four 
















Figure 3.3.  Artemisinin derivatives do not promote growth arrest in TGF-β 
resistant gastric cancer cell line, SNU5. Growth of SNU5 cells treated with 
artemisinin derivatives (GC001, GC003, GC006, GC008, GC009, GC010 and 
GC011) in a dose-dependent manner for a total duration of 24h, 48h, 72h or 96h was 
determined by MTT assay. The values plotted in bar graph are average of three 




























3.1.2 GC011 inhibits growth of TGF--sensitive gastric cancer cells but not 
in TGF-β-resistant gastric cancer cells or normal gastric cells. 
As GC011 displayed a high level of selective cytotoxicity for the TGF-β 
sensitive gastric cancer cell line SNU16 as compared to TGF-β resistant SNU5 
cells, this compound was selected for further testing and its activity screened 
on a panel of gastric cancer cell lines with differential sensitivity to TGF-β. As 
demonstrated in Figure 3.4, GC011 promoted a dose-dependent growth 
inhibition in both SNU16 and another TGF- sensitive gastric cancer cell line, 
SNU620,181-183 whereas gastric cancer cells that are resistant to TGF--
induced growth inhibition were not sensitive to GC011, suggesting that 
GC011 may act as a TGF-agonist. Additionally, both TGF-β and GC011 had 
no growth inhibitory effects on a normal gastric epithelial cell line, HFE-145, 
at the doses indicated (Fig. 3.4A & B). In SNU16 cells, the growth inhibition 
mediated by 1 µM GC011 was close to 35% after 96 hours of treatment, while 
at 5 uM concentration it was around 73% (Figure 3.4A). At comparable doses 
and time-points, most TGF- resistant gastric cancer cells were still resistant 
to GC011-induced growth inhibition (Figure 3.4A & B). As observed in the 
initial screening, the proliferation of TGF- sensitive SNU16 cells was 
inhibited in a dose-dependent manner with different concentrations of GC011 
(0, 1, 5 and 10 µM) at 48, 72 and 96 hours. Treatment with 5 µM and 10 µM 
of GC011 at different times (24, 48, 72 and 96 hours) demonstrated that cell 
growth was also inhibited in a time-dependent manner (Figure 3.5A). In 











Figure 3.4. GC011 promotes selective growth inhibition in TGF-β sensitive 
gastric cancer cells but not in TGF-β resistant gastric cancer cells and normal 
gastric cells. Growth of various gastric cancer cells treated with GC011 (A) or TGF-
β (B) in a dose-dependent manner for 96 hours was determined by MTS assay. The 
values plotted in bar graph are average of three independent experiments. All cell 
lines were cultivated and maintained under same culture conditions. *p < 0.05 and 












Figure 3.5. GC011 promotes selective growth arrest in TGF-β sensitive gastric 
cancer cells in a dose- and time-dependent manner. (A) SNU5 and (B) SNU16 
cells were treated with various concentrations of GC011 as stated for 24h, 48h, 72h, 
or 96h and growth was determined by MTS assay. The values plotted in bar graph are 
average of three independent experiments. All cell lines were cultivated and 






3.1.3 GC011 induces apoptosis in TGF-β sensitive SNU-16 cells. 
Apoptosis is a widely studied mechanism in antitumor therapy as its 
manipulation is an effective strategy for cancer control. As TGF-β signalling 
is known to contribute to growth arrest in cells by regulating apoptosis, we 
next investigated whether GC011-induced growth inhibition in TGF-β 
sensitive cells was mediated through apoptosis. The signaling mediated by 
TGF- contributes to growth arrest by inducing apoptosis characterized by the 
activation of PARP and caspase-3 through proteolytic processing.45 To this 
aim, we first determined the effect of GC011 on the viability of TGF-β 
sensitive SNU16 and SNU620 cells, as well as TGF-β resistant SNU5 cells, 
using a FACS based Annexin V assay. SNU5, SNU16 and SNU620 cells were 
treated with GC011 in a dose-dependent manner for a total duration of 96 
hours and stained with propidium iodide (PI) and fluorescence labelled 
Annexin V antibody, and relative percentage of apoptotic cells was then 
determined by flow cytometry. GC011 selectively induced apoptosis in TGF-β 
sensitive cells. This was demonstrated by an observed dose-dependent 
increase in FITC-Annexin–positive/PI-negative cells (early apoptotic) and 
FITC-Annexin/PI double-positive cells (late apoptotic) in TGF-β sensitive 
SNU16 and SNU620 cells. As expected, GC011 had no observable effect on 
SNU5 cells (Figure 3.6). Additionally, western blots revealed similar 
activation of caspase-3 and cleavage of PARP in both GC011 and TGF-










Figure 3.6. GC011 promotes apoptosis of TGF-β sensitive gastric cancer cells. 
Relative level of phosphatidylserine exposure, which is indicative of the extent of 
apoptosis in mammalian cells, in SNU5, SNU16 and SNU620 cells treated with 
GC011 in a dose-dependent manner for 96 hours was determined by FACS after 



















Figure 3.7. GC011 activates caspase-3 and PARP in TGF-β sensitive SNU16.  
Activation of PARP and caspase-3 in SNU16 and SNU5 cells treated with GC011 or 
TGF-β1 in a time-dependent manner was determined in western blotting assay 
performed with anti-PARP or anti-caspase-3 antibodies. As an indication of loading 











3.1.4 GC011 activates Smad signaling and up-regulates the expression of 
TGF-target genes in TGF-β sensitive cell line, SNU16.   
Given that only TGF-β-sensitive cells appear to be sensitive to GC011, we 
postulate that GC011 may act as a TGF-β agonist. In order to validate the 
hypothesis, the activation of the TGF-β signaling pathway in these cells was 
also investigated. The signal initiated by TGF- ligand is primarily transmitted 
across the cell through the phosphorylation and nuclear translocation of 
Smad2/3 proteins, which then co-operate with other Smad proteins to induce 
the expression of TGF- target genes such as PAI-1 and p21.184 To test 
whether GC011 could also induce the phosphorylation of Smad2/3 proteins as 
observed with TGF- stimulation, relative levels of Smad2 and Smad3 
proteins in SNU5 and SNU16 cells treated with 1 M GC011 in a time-
dependent manner was determined by western blotting assay. In SNU16 cells 
treated with 1 M GC011, the level of phosphorylated Smad3 protein was 
significantly enhanced within 8 hours of treatment and the level was 
maintained throughout the duration up to 24 hours (Fig. 3.8A). Level of 
phosphorylated Smad2 protein was also elevated within 24 hours in GC011-
treated cells relative to untreated cells (Fig. 3.8A). This GC011-induced 
increase in Smad2 and Smad3 phosphorylation was comparable to the increase 
in Smad2 and Smad3 phosphorylation induced by TGF-Fig. 3.8B). In 
contrast, no significant upregulation of Smad2/3 phosphorylation was 
observed in SNU5 cells (Fig. 3.8A & B). Attenuation of Smad levels in TGF-β 
treated cells was also observed, whereas in GC011 treated cells, the Smad 
levels were maintained. In TGF-β treated cells, the observed attenuation may 
be explained by the induction of the negative feedback mechanism that 
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normally controls the intensity and duration of TGF-β signaling response, 
through the activation of I-Smads and Smurfs. Although GC011 may activate 
the Smad signaling pathway, it is possible that it acts independently of the 
negative feedback loop. 
In addition to the phosphorylation of Smad2 and Smad3, real-time PCR 
analysis revealed a significant increase in the transcript levels of TGF-β target 
genes PAI-1 and p21 in SNU16 cells treated with GC011 (Fig. 3.9A). Protein 
expression of these two target genes are also up-regulated by GC011 
treatment, similar to that observed in TGF-treated SNU16 cells, but were 
unchanged in SNU5 cells (Fig. 3.9B).  
Next, a luciferase assay was performed on TGF-β responsive P19 embryonal 
carcinoma cells transfected with a reporter plasmid driven by mouse germ line 
IgCα promoter that contains a TGF-β-responsive element (TβRE) (Fig. 3.10A) 
[10]. Consistent with previous findings [11], TGF-β displayed a dose-
dependent increase in IgCα promoter activity in P19 cells, with the maximum 
increase achieved at 1.5 µM concentration (Figure 3.10B). Interestingly, 
GC011 also induced a nearly identical dose-dependent increase in IgCα 
promoter activity in P19 cells, suggesting that GC011 may exert a TGF-β like 
regulatory effect on the TGF-β-responsive promoter element (Figure 3.10C). 
Taken together, these findings collectively suggested that GC011-induced 
apoptosis of SNU16 cells could be an outcome of activation of the TGF--
































Figure 3.8. GC011 induces the phosphorylation of Smad2 and Smad3 in TGF-β 
sensitive cell line SNU16.  Level of phosphorylated Smad2 and Smad3 in SNU16 
and SNU5 cells treated with 1µM GC011 (A,C) or 1 ng/mL TGF-β (B,D) was 
determined by western blotting assay performed with (A,B) and quantitative 
densitometry analysis (C,D) of protein expression. For western blotting, level of 
Smad2 and Smad3 proteins in each sample was determined with anti-Smad2, anti-
Smad3, phospho-specific Smad2 or Smad3 antibodies. As an indication of loading 
control, level of total protein in each sample was determined by Coomassie Blue 
staining. For quantitative densitometry analysis, the values plotted in bar graph are 
average of three independent experiments. *p<0.05, **p<0.01 and ***p<0.001, 


























Figure 3.9. GC011 up-regulates the expression of TGF-β target genes in TGF-β 
sensitive SNU16.  Levels of p21 and PAI-1 mRNA and protein in SNU16 and SNU5 
cells treated with GC011 or TGF-β was respectively determined by real-time PCR 
analysis (A) and western blot using anti-p21 or anti-PAI-1 antibodies (B). As an 
indication of loading control, level of total protein in each sample was determined by 
Coomassie Blue staining. The values plotted in the bar graphs are average of three 





























Figure 3.10. GC011 activates the promoter of TGF-β responsive gene in TGF-β 
responsive P19 cells. (A) Smad binding motifs (indicated as S1, S2, and S3) in TGF-
β response element (TβRE) of mouse germ line IgCα gene are highlighted. (B & C) 
Effect of TGF-β1 or GC011 on the activity of a reporter plasmid driven by IgCα 
promoter that contains a TβRE was determined in P19 embryonal carcinoma cells. 
P19 cells were treated with TGF-β1 (B) or with GC011 (C) in a dose-dependent 
manner for a total duration of 24 hours. The values plotted in bar graph are average of 
three independent experiments. p values as compared with untreated controls. 
 
3.1.5 Growth inhibition induced by GC011 is dependent on the TGF-β 
signaling pathway. 
 
Using semi-quantitative PCR analysis, we first determined transcript levels of 
TGF-β1, TGF-β2, TGF-β3, TGF-β type I receptor (TβRI) and TGF-β type II 
receptor (TβRII) in our panel of gastric cancer cell lines and compared them 
with the TGF-β responsiveness as reported earlier in Section 3.16. Expression 
of TGF-β2 ligand was not detected in both TGF-β sensitive cell lines SNU16 
and SNU620 suggesting that there is no direct correlation with the 
responsiveness to growth inhibition by GC011 and the expression of TGF-β2. 
In concordance with previous reports,63,185 both SNU1 and SNU5 had no 
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detectable expression of TGF-βRII, which explains its loss of responsiveness 
to TGF-β-induced growth inhibition. There was no detectable TGF-β1 
expression in MKN7 and TMK1 cells. The remaining cell lines retained 
expression of all three TGF-β ligands and both TGF-β receptors, but are still 
resistant to TGF-β signaling (Fig. 3.11A).  
PCR analysis of cDNAs obtained from SNU16 cells treated with 1 µM of 
GC011 in a time-dependent manner revealed that only TGF-β1 mRNA 
expression was upregulated, further suggesting that the other two isoforms of 
TGF-β are not involved in GC011-induced growth inhibition (Fig. 3.11B). 
TGF-β1 protein levels examined with western blotting also showed a marked 
increase with GC011 treatment (Fig.3.11C). Additionally, GC011 treatment 
did not significantly affect the mRNA expression of both TGF-βI and TGF-βII 
receptors (Fig. 3.11B). 
To further determine the involvement of the TGF-βR-Smad signaling pathway 
in GC011-induced growth inhibition in SNU16 cells, we introduced siRNAs 
to suppress either TβRI, TβRII, Smad2 or Smad3 respectively to inactivate the 
TGF-β signaling pathway. As indicated in Figure 3.12A, silencing Smad2 
almost completely reversed growth inhibition induced by GC011, whereas 
Smad3 silencing reversed it to a lesser extent, despite the higher efficacy of 
Smad3 siRNA in downregulating Smad3 protein as compared to Smad2 
siRNA. This observation suggests that GC011 target genes may have a higher 
dependency on Smad2, as subtle alterations in Smad2 expression levels 
already cause a significant effect on GC011-mediated growth inhibition. 
Similarly, knockdown of TβRI and TβRII completely abolished the growth 
inhibition induced by GC011 in SNU16 cells (Fig. 3.12B). Treatment with 
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LY2157299, a potent and selective TGF-β receptor type I and type II inhibitor 
with IC50 of 86nM and 2nM respectively, also abrograted the growth 
inhibitory effects of GC011 in SNU-16 cells (Fig. 3.12C). 
Taken together, these ﬁndings suggest that activation of TGF-βR-Smad 
signaling is required for GC011-induced growth inhibition in SNU16 cells and 
that GC011 may also operate via directly upregulating TGF-β1 expression and 
therefore stimulating the TGF-βR-Smad signaling pathway to induce growth 




























Figure 3.11. Semi-quantitative PCR analysis of TGFβ genes in a panel of gastric 
cancer cell lines. (A) cDNAs were obtained from total RNA extracted from gastric 
cancer cell lines as indicated and TGF-β1, TGF-β2, TGF-β3, TβRI, and TβRII 
transcript levels were analysed by semiquantitative RT-PCR. (B) cDNAs obtained 
from total RNA extracts of GC011-treated SNU16 cells were subjected to 
semiquantitative RT-PCR. (C) Level of TGF-β1 protein in SNU16 cells treated with 1 













































































Figure 3.12. GC011-induced growth arrest is mediated by the TGF-β signaling 
pathway. (A) Effect of TGF-β gene knockdown on the proliferation of GC011-
treated SNU16 cells transfected with non-silencing control, Smad2, Smad3, TβRI, or 
TβRII siRNA was determined using MTS assay. The values presented in each bar 
represent the average of three independent experiments. *p < 0.05, **p < 0.01, ***p 
< 0.001, ****p < 0.0001, untreated vs GC011, and GC011 vs siRNA transfected 
cells. (B) Knockdown efficiency in experiments performed was determined by semi-
quantitative RT-PCR and its protein expression examined by western blotting. (C) 
SNU16 cells were treated with GC011 (1µM) in the presence and absence of 
LY2157299, a potent TGF-β receptor I (TβRI) inhibitor, and its effect on growth 
proliferation was determined by MTS assay. The values presented in each bar 
represent the average of three independent experiments. *p < 0.05, **p < 0.01, ***p 
< 0.001, ****p < 0.0001, untreated vs GC011, and GC011 vs LY2157299. 
 
3.1.6 GC011 induces down-regulation of N-CoR/HDAC1 in TGF-
βresponsive cells. 
Next, we aimed to understand the molecular mechanism underlying the 
difference in responsiveness towards TGF-β. In the nucleus, Smad 
heterodimers bind to various transcriptional factors and transcriptional 
activators and corepressors, leading to transcriptional regulation of target 
genes. N-CoR has been postulated to be part of the repressor complex targeted 
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to TGF-β target genes.184 As such, we investigated the status of N-CoR in the 
prototypical TGF-β sensitive and resistant cell lines, SNU16 and SNU5.  
Transcriptional control imparted by N-CoR is primarily mediated in the 
nucleus. Aberrant cytosolic distribution of N-CoR protein would imply 
dysregulation in N-CoR-mediated transcriptional control of target genes. To 
investigate a link between N-CoR status and TGF- responsiveness of gastric 
cancer cells, subcellular distribution of N-CoR protein in SNU16 and SNU5 
cells was determined using immunofluorescence assay. In TGF-sensitive 
SNU16 cells, relative level of nuclear N-CoR protein was significantly higher 
when compared to its level in TGF- resistant SNU5 cells, where its 
expression was mainly in the cytoplasm (Figure 3.13). As N-CoR is a 
corepressor, this data suggests that it is mislocalised in the cytoplasm and is 
thus non-functional in SNU5 cells. 
The notion that N-CoR function might have been compromised in TGF- 
resistant cells was further confirmed by the significantly lower level of N-CoR 
protein in SNU5 cells when compared to its level in SNU16 cells using 
western blotting assay (Figure 3.14).  
The ultimate outcome of TGF-β signaling on cell fate determinationis 
achieved through the sequential activation of downstream TGF-target genes 
which usually remain suppressed in the absence of TGF-stimulation. As 
observed in retinoic acid (RA) signalling, it is likely that an N-CoR containing 
chromatin remodeling complex also keeps a tab on TGF- target genes in the 
absence of TGF-βstimulation. Although there is no evidence yet, activation 
of TGF-βtarget genes would likely require abrogation of N-CoR/HDAC-
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mediated transcriptional repression followed by the recruitment of 
transcriptional activator complex containing DNA binding Smad proteins.186 
Therefore, to test whether TGF- or GC011 can antagonize any N-CoR-
mediated transcriptional repression through inducing N-CoR degradation or 
displacement as observed with retinoic acid, level of N-CoR protein in whole 
cell extracts of SNU5 and SNU16 cells treated with TGF-βor GC011 in a 
dose-dependent manner was determined using western blotting assay.  Both 
TGF-β and GC011 promoted a selective dose- and time-dependent down-
regulation of N-CoR protein in SNU16 cells, while in TGF- βresistant SNU5 
cells, no N-CoR down-regulation by either GC011 or TGF-β was observed 
(Figures 3.15A & B). GC011 also promoted a TGF-βlike down-regulation of 
HDAC1 protein in TGF- sensitive SNU16 cells but not in TGF-resistant 
SNU-5 cells (Figure 3.16). Additionally, siRNA-induced ablation of N-CoR 
led to a significant up-regulation of IgCα promoter activity in P19 cells 
(Figure 3.17A & 3.17B). These findings suggest that the artemisinin derivative 
GC011 can function as a potent TGF-β agonist and sensitize TGF-βsensitive 
SNU16 cells to apoptosis by overriding the N-CoR-induced transcriptional 










Figure 3.13. N-CoR localization is mainly cytosolic in TGF-β resistant SNU5 
cells but nuclear in TGF-β sensitive SNU16.  Subcellular distribution of N-CoR 
(red) in TGF-β resistant cell line, SNU5, and TGF-β sensitive cell line, SNU16, was 
determined by staining the cells with anti-N-CoR antibody and fluorescence-labelled 
secondary antibody. Nucleus was stained with DAPI (blue). Cells were visualised 





Figure 3.14. Level of N-CoR in TGF-β-resistant SNU5 cells is down-regulated as 
compared to that in TGF-β sensitive SNU-16 cells. Level of N-CoR protein in 
whole cell extracts of TGF-β sensitive SNU16 cells and TGF-β resistant SNU5 cells 
was determined in western blotting assay with N-CoR antibody. As an indication of 














Figure 3.15. GC011 induces down-regulation of N-CoR in TGF-β responsive 
cells. Level of N-CoR protein in whole cell extracts of SNU16 and SNU5 cells 
treated with GC011 or TGF-β was determined in western blotting assay with anti-N-
CoR antibody (A). Level of N-CoR protein in whole cell extracts of SNU16 cells 
treated with GC011 or TGF-β in a time-dependent manner was determined in western 
blotting assay with N-CoR antibody (B). As an indication of loading control, level of 
































Figure 3.16. GC011 induces down-regulation of HDAC1 in TGF-β responsive 
cells. Level of HDAC1 protein in whole cell extracts of SNU16 and SNU5 cells 
treated with vehicle or GC011 in a dose and time-dependent manner was determined 
in western blotting assay with HDAC1 antibody. As an indication of loading control, 





















Figure 3.17. N-CoR silencing activates the promoter of TGF-β responsive gene.  
Effect of N-CoR ablation (A) on the activity of the IgCα promoter was determined by 
relative luciferase assay performed in P19 cells transfected with control or anti-N-
CoR siRNA (B). The values plotted in the bar graph are average of three independent 








3.2 RUNX3 induces degradation of N-CoR via the ubiquitin-proteosome 
pathway and possibly regulates N-CoR-mediated repression of TGF-β 
target genes. 
3.2.1 Loss of RUNX3 protein expression in gastric cancer cells 
Almost all gastric cancer cell lines have an impaired TGF-β signaling 
pathway, and are resistant to TGFβ (Fig. 3.4). RUNX3, a known tumor 
suppressor in gastric cancer, has been shown to form complexes with receptor-
regulated Smads (R-Smads) that regulate target gene expression, making it is a 
downstream target of the TGF-β signaling pathway. Its role in TGF-β-induced 
apoptosis has also been well-documented. Another member of Runt-related 
transcription factor family, RUNX1, has also been linked to carcinogenesis, 
although its involvement has been better studied in leukemia. As GC011 also 
appeared to be inducing TGF-β-mediated growth inhibition and apoptosis in 
SNU16 cells, we postulate that RUNX may also be a downstream target of 
GC011. We therefore first examined RUNX1 and RUNX3 protein expression 
in gastric cancer cell lines. Consistent with previous reports, RUNX3 protein 
was lost in most of the gastric cancer cell lines (11 out of 13),62 but was highly 
expressed in TGF-β responsive SNU16 cells. Amongst the TGF-β resistant 
cell lines, only SNU1 expressed RUNX3, while the expression level was very 
low in SNU5 cells. Expression of RUNX1 was detectable in most of the 






Figure 3.18. Expression of RUNX1 and RUNX3 protein in gastric cancer cell 
lines.  Whole cell extracts were prepared from a panel of human gastric cancer cell 
lines and 10 µg of crude lysates were resolved by SDS-PAGE. RUNX1 and RUNX3 
protein expression were determined via western blotting with anti-Runx1 or anti-




3.22 RUNX1 and RUNX3 promote N-CoR degradation.  
Previous reports have shown that TGF-β stimulation induces nuclear 
translocation of RUNX3 in SNU16 cells, where it performs its function as a 
transcription factor. We have also shown that N-CoR is primarily localised in 
the nucleus of TGF-β sensitive cells. As TGF-β1 selectively promotes down-
regulation of N-CoR and HDAC1 proteins in TGF-β sensitive cells (Fig. 3.12 
& 3.13), we hypothesize that RUNX3 may play a role in TGFβ-induced N-
CoR/HDAC1 loss. To demonstrate this, we ectopically expressed flag-tagged 
N-CoR in 293T cells along with RUNX1, RUNX2 and RUNX3, and determined 
the level of exogenous N-CoR protein via western blotting. Cells transfected 
with RUNX1 and RUNX3 exhibited a marked loss in the expression of flag-
tagged N-CoR, whereas transfection with RUNX2 did not result in any 
significant downregulation (Fig. 3.19). This finding suggests a putative role of 




Figure 3.19. RUNX1 and RUNX3 promote the degradation of N-CoR protein. 
293T cells were transfected with N-CoR-FLAG expression plasmid and plasmids 
expressing RUNX1, RUNX2 or RUNX3. The N-CoR levels were examined by 
Western blotting and determined using anti-FLAG antibody. As an indication of 
loading control, level of total protein in each sample was determined by Coomassie 
Blue staining. (*Contributed by Pang Sze Li) 
 
 
3.23 RUNX1 and RUNX3 induce translocation of nuclear N-CoR into 
cytoplasm. 
To examine whether Runx1/3-induced degradation of N-CoR was associated 
with any deregulated subcellular distribution, we next assessed the subcellular 
localization of ectopically expressed flag-tagged N-CoR protein in 293T cells 
co-transfected with RUNX1, RUNX2 or RUNX3 using immunofluorescence 
staining analysis. Ectopic N-CoR was predominantly confined to the nucleus 
in cells transfected with empty vector, but when cells were co-transfected with 
RUNX1 and RUNX3, expression of ectopic N-CoR was observed to be mainly 
cytosolic. As expected, N-CoR signal was also significantly weaker in cells 
co-transfected with RUNX1 and RUNX3, probably as a result of Runx1- or 
Runx3-induced degradation of N-CoR. As expected, transfection of RUNX2 
did not result in any translocation of N-CoR. As such, it is likely that Runx1 
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and Runx3 are involved in the export of N-CoR from the nucleus to the 
cytosol where it is then targeted for degradation. 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
Figure 3.20. RUNX1 and RUNX3 induce the translocation of nuclear N-CoR to 
cytosol. 293T cells were transfected with the N-CoR-FLAG expression plasmids and 
with either empty pACT vector or expression vectors encoding RUNX1, RUNX2 or 
RUNX3.  The exogenous N-CoR signals were detected by anti-FLAG antibody 
(green) and nuclear DNA was stained with DAPI (blue). In the panels indicated as 





3.24 RUNX1 and RUNX3 induce the ubiquitination of N-CoR 
Next, to determine if Runx1/Runx3-induced proteolytic degradation of N-CoR 
was via a proteosomal pathway, we first tested the effect of a known 
proteasome inhibitor, MG132, on Runx1 and Ruunx3 mediated degradation of 
N-CoR. 293T cells co-transfected with flag-tagged N-CoR expression 
plasmids and RUNX1, RUNX3 or empty vector, were subsequently treated 
with MG132 and N-CoR expression was determined by western blotting. It 
was observed that MG132 significantly inhibited both Runx1 and Runx3-
induced degradation of N-CoR protein, suggesting that N-CoR undergoes 
proteosomal degradation in the presence of Runx1 and Runx3 (Fig. 3.21).  
As majority of intracellular proteins are degraded by the ubiquitin-proteosome 
pathway (UPP), an in vivo ubiquitination assay was subsequently performed 
on 293T cells by co-expressing Flag-tagged N-CoR and Myc-ubiquitin along 
with empty vector or vector expressing RUNX1 or RUNX3. Flag-tagged N-
CoR was immunoprecipitated with anti-Flag antibody and level of ubiquitin-
conjugated N-CoR was then determined by western blotting with anti-myc 
antibody. As shown in Fig. 3.22, both Runx1 and Runx3 augmented the 
conjugation of ubiquitin to N-CoR. Taken together, these results suggest that 
ubiquitin-mediated proteosomal proteolysis may be the major mechanism of 













Figure 3.21. MG132 significantly reverses Runx1- and Runx3-induced 
degradation of N-CoR protein. 293T cells transfected with the N-CoR-FLAG 
expression plasmid and plasmids expressing RUNX1, RUNX2 or RUNX3 were treated 
with MG132. N-CoR-FLAG was immunoprecipitated and its expression was detected 
by western blotting with anti-FLAG antibody. As an indication of loading control, 
level of total protein in each sample was determined by Coomassie Blue staining. 






















Figure 3.22. N-CoR degradation by Runx3 is mediated by the ubiquitin-
proteosome pathway (UPP). 293T cells were transfected with the N-CoR-FLAG 
expression plasmid, myc-ubiquitin plasmid, and plasmids expressing RUNX1 (A) or 
RUNX3 (B), and subsequently treated with MG132. N-CoR-Flag was 
immunoprecipitated with anti-FLAG antibody, and level of ubiquitinated complexes 
were detected by western blotting using anti-c-myc antibodies. (C) The levels of N-
CoR-FLAG and RUNX3 in each sample was examined by Western blotting and 





3.25 Deletion analysis of RUNX1 and RUNX3 reveals intrinsic domains 
linked to N-CoR degradation  
To investigate which domains of RUNX1 and RUNX3 are involved in N-CoR 
degradation, we assessed the effect of five deletion mutants on Runx1/3-
mediated N-CoR degradation. The N-terminal sequence and part of the DNA-
binding Runt homology domain was deleted in RUNX1.1 whereas the entire 
N-terminus and Runt domain was abolished in RUNX1.2. RUNX3.1 
contained only the N-terminal sequence and the Runt domain, whereas 
RUNX3.2 contained only the transcription activation domain, transcription 
inhibitory domain, and a conserved VWRPY sequence at the C-terminal. Only 
the N-terminus was deleted in RUNX3.3 (Fig. 3.23). 293T cells were 
transfected with flag-tagged N-CoR and the deletion mutants and the effect of 
each deletion construct on the level of exogenous N-CoR was analysed by 
western blotting. 
Both RUNX1 constructs containing deletions in the N-terminal sequence and 
the conserved Runt domain significantly inhibited N-CoR degradation, 
although RUNX1.1, which only lacked part of the Runt domain, abrogated N-
CoR degradation to a lesser extent. While this suggests a role of the N-
terminus and Runt domain in N-CoR degradation, the deletion of N-terminus 
in the RUNX3.3 mutant however did not abolish N-CoR degradation, 
implying that the N-terminal sequence is not required for N-CoR degradation. 
Additionally, construct RUNX3.2, which also lacked the Runt domain, only 
weakly inhibited N-CoR degradation. This suggests the involvement of other 
domains other than the Runt domain in N-CoR degradation. This might also 
explain why RUNX2 does not play a role in N-CoR degradation, despite 
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sharing the same conserved Runt domain with RUNX1 and RUNX3 (Fig. 
3.24).  
Consistent with this notion, we found that deletion construct RUNX3.1, which 
only contained the N-terminus and Runt domain, could not completely inhibit 
the degradation of N-CoR (Fig. 3.24). The data thus far suggests that both the 
Runt domain and the distal C-terminal sequence exert effects that are required, 





Figure 3.23. A schematic representation of RUNX1, RUNX3 and their 
deletion derivatives. The numbers indicate the positions of the amino acids that 
flank each of the protein domains shown above. AD: activation domain; ID: 



































Figure 3.24. Mapping of intrinsic domains of RUNX1 & RUNX3 involved in N-
CoR degradation. 293T cells were co-transfected with N-CoR-FLAG expression 
plasmid and plasmids expressing deletion mutants of RUNX1 and RUNX3 as 
indicated in Figure 3.23. The N-CoR protein levels were determined using anti-FLAG 
antibody. As an indication of loading control, level of protein in each sample was 


















3.26 N-CoR overexpression abrogrates Runx3-induced activation of TGF-β 
responsive promoter, Ig Cα. 
We have shown that ablation of N-CoR significantly enhanced the 
transcriptional activation of the IgCα promoter, suggesting that N-CoR may 
play a part in the repression of TGF-β target genes. As Runx3 is a downstream 
target of the TGF-β signaling pathway, and also induces the cytoplasmic 
translocation and degradation of N-CoR, we hypothesize that N-CoR-
mediated repression of TGF-β target genes may be mediated by Runx3.  
As previously reported,69 the IgCα germline promoter contained both TGF-β 
responsive element and RUNX binding sites. P19 cells were again transfected 
with IgCα reporter plasmids and increasing amounts of Runx3 plasmids at the 
indicated amounts, and luciferase activity was monitored. As expected, 
transcriptional activity of the promoter was significantly enhanced by Runx3, 
in a dose-dependent manner (Fig. 3.25). Next, we assessed the effect of N-
CoR overexpression on the RUNX3-induced activation of the promoter. The 
transcriptional activation of the promoter induced by Runx3 was significantly 
decreased only when 1 µg of N-CoR-Flag was introduced into the cells, 
suggesting that overexpression of N-CoR abrogates Runx3-induced activation 
of the IgCα promoter (Fig. 3.26A). When 0.5 µg of N-CoR plasmids was 
transfected into the cells, N-CoR protein expression was almost undetectable, 
probably because Runx3 could still sufficiently promote N-CoR degradation 
(Fig.3.26B). Accordingly, transcriptional activity of the promoter promoted by 
Runx3 was not inhibited at this amount (Fig.3.26A). The data collectively 
suggests that interaction between N-CoR and Runx3 may play a role in 








Figure 3.25. Runx3 significantly enhances the transcriptional activity of the 
TGF-β responsive IgCα promoter. P19 cells were transfected with 0.15 µg of 
reporter plasmids and expression plasmids containing either empty vector or Runx3 at 
the indicated amounts, and the luciferase activity was determined. The values plotted 
in the bar graph are average of three independent experiments. p values as compared 





























Figure 3.26. Overexpression of N-CoR abrogates Runx3-induced activation of 
the IgCα promoter. (A) P19 cells were transfected with 0.15 µg of reporter plasmid, 
0.3 µg of Runx3 plasmid, and expression plasmids encoding flag-tagged N-CoR in 
the indicated combinations, and the luciferase activity was determined. The values 
plotted in the bar graph are average of three independent experiments. (B) Level of 
N-CoR and RUNX3 was determined by western blotting using anti-flag antibody and 
anti-RUNX3 antibodies respectively. As an indication of loading control, level of 
protein in each sample was determined by Coomassie Blue staining. p values, as 









3.3 N-CoR is misfolded in gastric cancer. 
3.31 N-CoR loss in gastric cancer cells is a post-transriptional event.  
The identification of GC011 as a potent inducer of TGF-β growth inhibitory 
pathway is potentially useful in clinical scenarios in which responsiveness to 
the tumor suppressive signals of the TGF-β pathway still remains, such as 
early stage cancers, or for a selected group of TGF-β sensitive tumor subtypes. 
However, gastric cancer cells which are no longer sensitive to the growth 
inhibitory effects of TGF-β would be resistant to GC011 treatment, indicating 
a need for an alternative therapeutic approach for such cases. 
Previously, our laboratory has reported a role of misfolded conformation 
dependent loss (MCDL) of N-CoR in the pathogenesis of acute promyelocytic 
leukemia (APL)187 and subsequently identified inhibition of N-CoR 
misfolding as an attractive strategy for treatment. Since we have previously 
determined that N-CoR protein in TGF-β resistant cell line SNU5 was down-
regulated (Fig. 3.11) and aberrantly localized in the cytosol (Fig. 3.10), we 
postulate that an APL-like loss of N-CoR may be involved in gastric cancer as 
well. To determine this, we proceeded to investigate the status of N-CoR in a 
panel of commercially available gastric cancer cell lines. Western blot analysis 
of whole crude extracts of the cell lines revealed N-CoR protein to be 
differentially expressed. In concordance with our previous findings, TGF-β 
sensitive cell lines SNU16 and SNU620 expressed N-CoR at the protein level. 
Compared to these two cell lines, N-CoR protein expression was significantly 
downregulated in most of the remaining cell lines (Fig. 3.27). This observed 
downregulation of N-CoR in gastric cancer cells was not seen at the 
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transcriptional level, as both semi-quantitative PCR and real-time PCR 
analysis revealed no significant downregulation of transcript levels as 
compared to SNU16 cells (Fig. 3.28). This data suggests that the observed N-
CoR loss in the remaining cell lines is likely a post-transcriptional event. 
 
 
Figure 3.27. Differential N-CoR protein expression in gastric cancer cell lines.  
Whole cell extracts were prepared from a panel of human gastric cancer cell lines and 100 
µg of each sample were resolved in SDS-PAGE. N-CoR protein expression was 
determined via western blotting with anti-N-CoR antibody. β-actin expression was used 























Figure 3.28. Loss of N-CoR protein expression is a post-transcriptional event.  
Low levels or loss of N-CoR protein expression in gastric cancer cell lines do not 
correlate with N-CoR transcript expression as determined by semi-quantitative PCR 
(A) and real-time PCR (B) analysis. Relative expression of N-CoR gene gastric 
cancer cell lines were determined by real time PCR analysis. Data was analyzed using 
the comparative Ct method using the expression level N-CoR gene in SNU-16 cells 
as the reference value, and the level of expression of the HPRT gene was used as 
control. Raw Ct values which registered as undetermined were set to 40. (Results 









3.32 N-CoR is predominantly mislocalized in the cytosol of most gastric 
cancer cell lines and is linked to ER stress. 
In its normal state, N-CoR is a ubiquitously expressed corepressor which 
mediates repression associated with nuclear receptors and a myriad of other 
transcription factors in the nucleus. Previous studies in our laboratory have 
determined that N-CoR in its native conformation is soluble in buffers 
containing organic detergent and is largely confined to the nucleus, whereas 
misfolded N-CoR is detergent-insoluble, largely localized in the endoplasmic 
reticulum, and is associated with ER stress amplification.  As N-CoR protein 
in majority of the gastric cancer cells was shown to be significantly 
downregulated, we hypothesized that this N-CoR loss may be triggered by its 
misfolding. To test this possibility, we first analysed the subcellular 
distribution of N-CoR in gastric cancer cell lines by immunofluorescent 
staining. The results demonstrated that a significant amount of N-CoR was 
detected in the cytoplasm of most of the gastric cancer cell lines. In contrast, 
N-CoR was mainly localized in the nucleus of TGF-β-sensitive cell lines, 
SNU16 and SNU620 (Fig. 3.29A). Consistent with this data, western blot 
analysis of nuclear and cytoplasmic extracts of SNU16, SNU620, SNU5 and 
MKN74 cells respectively indicated that while majority of N-CoR was found 
in the nuclear fractions of TGF-β responsive SNU16 and SNU620 cells, N-
CoR was largely cytoplasmic in SNU5 and MKN74 cells (Fig. 3.29B).  
Next, we assessed the solubility of N-CoR protein in three cell lines, SNU5, 
SCH and SNU16 cells in organic detergent NP-40. Consistent with our 
hypothesis that N-CoR is misfolded in most gastric cancer cells, it was found 
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that a significant portion of N-CoR detected in SNU5 and SCH was insoluble 
in NP-40 detergent. In contrast, N-CoR in SNU-16 cells was largely detected 
in the soluble fraction, further indicating that the N-CoR in SNU16 cells is not 
compromised in its conformation (Fig. 3.30).  
To investigate if misfolded N-CoR in gastric cancer cells contributes to ER 
stress amplification, expression levels of ER resident proteins GRP78 and PDI 
protein in gastric cancer cells was determined. The data revealed that both 
GRP78 and PDI levels was significantly higher across all gastic cancer cell 
lines as compared to that observed in SNU16 cells, which expressed N-CoR 
mainly in the nucleus, suggesting that the presence of misfolded N-CoR in the 
other cell lines was responsible for the increased ER stress levels observed 
(Fig. 3.31). These findings collectively indicated a role of misfolded N-CoR in 



























Figure 3.29. Aberrant cytoplasmic N-CoR is present in all gastric cancer cell 
lines, with the exception of TGF-β sensitive SNU16 and SNU620 cells. Subcellular 
distribution of N-CoR was determined in various gastric cancer cells by 
immunofluorescence staining and fractionation assay. (A) Cells were stained with an 
anti-N-CoR antibody (red) and counterstained with DAPI for nuclear detection (blue) 
and cells were visualised using confocal microscopy. (B) 100 µg (SNU16 & 
SNU620) or 200 µg (SNU5 & MKN74) of nuclear and cytoplasmic extracts were 
loaded for western blotting for detection of N-CoR with anti-N-CoR antibody. Level 
of lamin (nuclear marker) and tubulin (cytoplasmic marker) was determined to check 




Fig. 3.30. A significant portion of N-CoR protein in SNU5 and SCH cell lines is 
detergent-insoluble, whereas N-CoR in SNU16 cells is largely soluble. Protein 
solubility assay was performed on SNU5, SCH and SNU16 cell lines to determine the 
relative solubility of N-CoR protein in detergent. Soluble (S) and insoluble (I) 
fractions were obtained and N-CoR level in each fraction was determined by western 




















Fig. 3.31. Misfolded N-CoR in gastric cancer cells is linked to ER stress 
amplification. Relative level of ER stress in gsatric cancer cells was analysed by 
determining the levels of native and high molecular weight (HMW) PDI and GRP78 
proteins via western blotting with anti-PDI and anti-GRP-78 antibodies. As an 
indication of loading control, level of protein in each sample was determined by 












3.33 N-CoR is mislocalized in the cytosol of human gastric tissue. 
Next, we performed western blot analysis of crude protein extracts from 
human stomach tumor tissues, with extract from 293T cells as a positive 
control for N-CoR protein expression. Our results demonstrated that N-CoR 
expression at the protein level was also significantly reduced in clinical 
specimens (Fig. 3.32A). Additionally, immunohistochemical staining of a 
tissue array containing biopsy cores from human gastric tissue, both normal 
and tumor, showed that nuclear N-CoR was excluded from about 82% of the 
tumor cores (44 out of 54), 18.5% (10 out of 54) expressed N-CoR in both 
nucleus and cytoplasm, and all 54 tumor samples exhibited cytoplasmic 
distribution. In contrast, majority of the normal tissue samples displayed N-
CoR in both nucleus and cytoplasm (88.9%, 8 out of 9) (Fig. 3.32B). 
Collectively, these findings suggested that the reduction of N-CoR protein 
expression and its aberrant cytoplasmic localization appear to be general traits 
of human gastric cancer cell lines and tumors, and that these traits may arise as 



















Figure 3.32. N-CoR expression and localisation in human gastric tissue. (A) 
Crude extracts from patient tumor tissue are analysed via western blot for expression 
of N-CoR using anti-N-CoR antibody. (B) Immunohistochemistry staining of a tissue 
microarray of biopsy cores from human gastric tissue, both tumor and normal, using 
anti-N-CoR antibody. Counterstaining was done with hematoxylin. The boxed 


























3.4 Bortezomib, a 26S proteasome inhibitor, therapeutically targets the 
UPR pathway in gastric cancer by inhibiting the degradation of misfolded 
N-CoR. 
3.41 Bortezomib promotes growth arrest in gastric cancer cells. 
Previous findings in our laboratory have associated endoplasmic reticulum-
associated degradation (ERAD) and protease-mediated degradation of 
misfolded N-CoR with resistance to UPR-induced apoptosis in APL.188 As N-
CoR in gastric cancer cells appear to be misfolded, we postulated that 
inhibition of misfolded N-CoR degradation in these cells may sensitize them 
to UPR-induced apoptosis. Bortezomib, a dipeptidyl boronic acid compound 
that reversibly blocks the proteolytic activity of the proteasome, is an FDA-
approved drug for the treatment of multiple myeloma (MM), and various 
studies have reported its antitumor activities on other cancer types, including 
gastric cancer.166-170 It has been reported that treatment of MM cells with 
bortezomib causes the abnormal accumulation or misfolding of Ig proteins 
within ER by suppressing ERAD, thus inducing ER stress and UPR, which 
eventually leads to the induction of apoptosis.153,189 Therefore, we decided to 
investigate the effects of bortezomib in gastric cancer cells and determine if a 
similar mechanism underlies its antitumor activity. 
We firstly examined the effect of bortezomib on growth of 12 gastric cancer 
cell lines as well as immortalized normal human gastric epithelial cell line, 
HFE-145. Cells were treated with bortezomib at concentrations ranging from 
50 nM to 1 µM, for 24, 48 or 72 hours, and cell viability was measured by 
MTS assay. Results showed that bortezomib inhibited cell growth in a time 
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and concentration-dependent manner. While the gastric cancer cell lines 
displayed differential sensitivity to bortezomib, most of the cell lines showed 
significant growth imhibition with the lowest concentration of 50 nM 
bortezomib by 48 hours (Fig. 3.33B). In MKN74 cells, growth inhibition by 
50 nM bortezomib was about 25% at 24 hours (Fig. 3.33A), and increased to 
81% at 72 hours (Fig. 3.33C). Growth of SCH cells were already significantly 
inhibited at 24 hours (Fig. 3.33A) with 53% growth inhibition which increased 
to 84% at 72 hours (Fig. 3.33C). It was noted that even after 72 hours at 
maximal concentration of 1 µM of bortezomib treatment, cell growth of HFE-
145 cells were not inhibited (Fig. 3.33). These data suggests that bortezomib at 
low concentration significantly inhibits growth of gastric cancer cells, but not 



















Figure 3.33. Bortezomib inhibits growth of gastric cancer cells in a time- and 
dose-dependent manner, but does not affect growth of normal HFE-145 cells. 12 
gastric cancer cell lines and an immortalized human normal gastric epithelial cell line, 
HFE-145, were treated with various concentrations of bortezomib for the durations as 
indicated and the growth kinetics of the treated cells was measured by the MTS assay. 







3.42 Bortezomib activates the apoptotic pathway in gastric cancer cells. 
 
We then focused on MKN74 cells to further analyse the cellular response to 
bortezomib. To confirm whether the observed bortezomib-mediated growth 
inhibition was associated with apoptosis, we next performed fluorescence-
activated cell sorting (FACS) on cells stained with AnnexinV-FITC/PI. In line 
with the growth inhibition data, bortezomib treatment potently induced 
apoptosis of MKN74 cells after 48 hours. This was shown by a dose-
dependent increase in FITC-Annexin-positive/PI-negative early apoptotic cells 
and FITC-Annexin-positive/PI-double positive late apoptotic cells, from 
32.7% cell death detected at 12.5 nM bortezomib, to 56.7% cell death at 50nM 
(Fig. 3.34). 
We next assessed the effect of bortezomib treatment on protein levels of 
members of the apoptotic machinery; namely caspase-3, -9 and poly (ADP-
ribose) polymerase (PARP). Again, MKN74 cells were treated with 
bortezomib ranging from 0 to 50 nM for 24 hours. As expected, bortezomib 
treatment resulted in a dose-dependent caspase-9 and caspase-3 activation, as 
well as PARP cleavage (Fig. 3.35). Taken together, the data therefore suggests 













Figure 3.34. Bortezomib induces apoptosis in MKN74 cells. MKN74 cells were 
treated with increasing concentrations of bortezomib as stated for 48 hours. 
Fluorescence-activated cell sorting analysis was performed on the cells after reaction 














Figure 3.35. Bortezomib activates the apoptotic pathway in MKN74 cells. 
MKN74 cells were treated with bortezomib in a dose-dependent manner for 24 h. 
Western blot analysis of the crude lysates prepared in SDS lysis buffer were carried 
out using anti-caspase 9, anti-caspase 3, and anti-PARP antibodies. β-actin expression 








3.43 Bortezomib promotes the accumulation of misfolded N-CoR by 
blocking its degradation of N-CoR in gastric cancer cells. 
 The protein expression of N-CoR was previously screened in a panel of 
gastric cancer cell lines, and it was found that N-CoR expression was 
downregulated in most cell lines. To investigate if bortezomib has any effect 
on N-CoR expression, western blot analysis was carried out on MKN74 cells 
treated with increasing concentrations of bortezomib (0-50 nM) for 24 hours. 
The resulting data revealed that treatment of MKN74 cells with bortezomib 
led to a stabilization of N-CoR protein in a dose-dependent manner (Fig. 
3.36A). Treatment of two other cell lines, SCH and SNU5, with 50 nM 
bortezomib at 24 hours likewise resulted in an upregulation of N-CoR protein 
expression (Fig. 3.36B).  
It was postulated that bortezomib may cause accumulation of misfolded N-
CoR, similar to the accumulation of misfolded Ig in multiple myeloma. To test 
this hypothesis, the subcellular distribution and solubility of N-CoR stabilized 
by bortezomib were assessed. Western blot analysis of the nuclear and 
cytoplasmic extracts of bortezomib-treated MKN74 cells revealed that 
bortezomib led to a significant accumulation of N-CoR in the cytoplasm of 
MKN74 cells in a dose-dependent manner (Fig. 3.37A). In contrast, the level 
of N-CoR in the nuclear extracts increased to a much smaller extent with 
bortezomib treatment. Solubility assessment of N-CoR in bortezomib-treated 
MKN74 cells also showed that detergent-insoluble N-CoR accumulated to a 
much greater extent as compared to detergent-soluble N-CoR (Fig. 3.37B). 
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Together, these data suggest that bortezomib promotes the accumulation of 
misfolded N-CoR in the cytoplasm. 
Several studies have identified the involvement of several kinases in the 
regulation of co-repressor function. IKKα (inhibitor of nuclear factor kappa-B 
kinase subunit alpha kinase) and MEKK-1 (MEK-1 kinase), both serine-
threonine protein kinases, have been shown to phosphorylate SMRT (silencing 
mediator for retinoid and thyroid hormone receptors), another major nuclear 
receptor co-repressor closely related to N-CoR, resulting in its nuclear 
export190,191 N-CoR has likewise been shown to be phosphorylated by IKKα.94 
Other than altering the receptor interaction properties of corepressors, 
phosphorylation of corepressors has also been proposed to change its 
subcellular distribution from a nuclear to a cytoplasmic distribution, thereby 
relieving it of its repressive function on target gene expression. Previous 
studies in our laboratory also suggest that post-translational modification such 
as glycosylation, phosphorylation, and ubiquitination may significantly alter 
the conformation and function of N-CoR. To investigate if N-CoR misfolding 
in gastric cancer cells is also accompanied by a similar post-translational 
modification, level of serine-threonine phosphorylation in misfolded N-CoR 
stabilized by bortezomib was determined. N-CoR in bortezomib-treated 
MKN74 cell extracts was immunoprecipitated using anti-N-CoR antibody, 
resolved by SDS-PAGE, and western blot analysis was carried out for 
detection of serine/threonine phosphorylation using anti-pan-phospho 
serine/threonine antibody. The results showed that the N-CoR in MKN74 cells 
were phosphorylated at the serine/threonine residues, and stabilized N-CoR 
following bortezomib treatment also displayed serine/threonine 
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phosphorylation (Fig. 3.38). The concomitant increase of phosphorylation 
level and N-CoR protein stabilized by bortezomib treatment suggests that 
while phosphorylation of N-CoR in MKN74 may possibly play a role in its 
misfolding or aberrant localisation, bortezomib does not inhibit its aberrant 
phosphorylation to rescue its native conformation. This further suggests that 
bortezomib promotes the accumulation of misfolded N-CoR, possibly by 









Figure 3.36. Bortezomib stabilises N-CoR in gastric cancer cells. (A) MKN74 
cells were treated with increasing doses of bortezomib as stated for 24 h and protein 
extracts were prepared in SDS loading buffer. (B) SNU5 and SCH cells were treated 
with 50 nM of bortezomib for 24 hours and crude extracts were obtained. N-CoR was 
detected by western blotting using anti-N-CoR antibody and level of β-actin 






Figure 3.37. Misfolded N-CoR accumulates in the cytoplasm of MKN74 cells 
with bortezomib treatment. (A) MKN74 cells were treated with increasing doses of 
bortezomib as stated for 24 hours and nuclear and cytoplasmic extracts were 
obtained. N-CoR was detected by western blotting using anti-N-CoR antibody. Level 
of lamin (nuclear marker) and tubulin (cytoplasmic marker) was determined to check 
for cross contamination of nuclear and cytoplasmic extracts and also as loading 
controls. (B) Protein solubility assay was performed on MKN74 cells treated with 50 
nM bortezomib for 24 hours to determine the relative solubility of N-CoR protein in 
detergent. Soluble (S) and insoluble (I) fractions were obtained and N-CoR level in 
each fraction was detected by western blotting using anti-N-CoR antibody. Level of 



















Figure 3.38. Misfolded N-CoR in MKN74 cells displays aberrant 
serine/threonine phosphorylation. Levels of serine/threonine phosphorylated N-
CoR in MKN74 cells treated with bortezomib was determined by staining the 
immunoprecipitated N-CoR protein with a pan-phospho serine/threonine antibody. 
An aliquot of immunoprecipitated N-CoR was also stained with N-CoR antibody. 
Level of total N-CoR protein pulled down in each treated sample was determined by 









3.44 Bortezomib inhibits the trypsin-like, chymotrypsin-like and caspase-
like activities of the proteasome in MKN74 cells. 
Given its function as a proteasome inhibitor, it is very likely that accumulation 
of misfolded N-CoR by bortezomib is a result of its inhibition of the 
proteasome. To validate this hypothesis, a proteasome activity assay was 
performed to measure proteosomal activity in MKN74 cells treated with 0 - 50 
nM bortezomib for 4 or 24 hours. Three proteolytic activities associated with 
the proteasome (chymotrypsin-like, trypsin-like, and caspase-like) were 
measured. The results showed that bortezomib treatment significantly 
inhibited all three proteolytic activities of the proteasome, in a dose- and time-
dependent manner. Significant proteosomal inhibition was already detected at 
4 hours post treatment with bortezomib (Fig. 3.39). This data suggests that 
accumulation of misfolded N-CoR mediated by bortezomib is most likely due 







Figure 3.39. Velcade inhibits the trypsin-like, chymotrypsin-like and caspase-like 
peptidase activities of the proteasome. Crude extracts obtained from MKN74 cells 
treated with 0 – 50 nM of curcumin for 4 hours and 24 hours show reduced 















3.45 Bortezomib promotes ER stress amplification in MKN74 cells. 
It has been shown that bortezomib promotes accumulation of insoluble N-CoR 
in the cytoplasm of MKN74 cells (Figure 3.37). To test if accumulation of N-
CoR mediated by bortezomib is linked to amplification of ER stress, protein 
levels of ER stress markers, GRP78, HSP60 and PDI, was determined by 
western blot analysis of bortezomib-treated MKN74 cells. Bortezomib 
induced the formation of high molecular weight (HMW) PDI in a dose-
dependent manner (Fig. 3.40A). Additionally, treatment of bortezomib for 
different time points also indicated the upregulation of GRP78 and HMW 
HSP60 and PDI expression in a time-dependent manner (Fig. 3.40B). 
Collectively, these data suggest that bortezomib contributes to ER stress via 






















Figure 3.40. Bortezomib promotes formation of HMW ER stress markers 
GRP78, PDI and HSP60 in a dose- and time-dependent manner. (A) MKN74 
cells were treated with bortezomib in a dose-dependent manner at the concentrations 
indicated for 24 hours. Western blot detection was carried out on the crude extracts 
using anti-PDI antibody. (B) MKN74 cells were treated with 50 nM of bortezomib in 
a time-dependent manner between 0-48 hours. Western blot detection was carried out 
on the crude extracts using anti-GRP78, anti-HSP60 and anti-PDI antibodies. Level 
of β-actin expression was determined as an indication of loading control. 
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3.46 Bortezomib induces UPR-induced apoptosis in MKN74 cells.  
So far, bortezomib has been shown to induce the accumulation of misfolded 
N-CoR in MKN74 cells, which resulted in amplification of ER stress (Fig. 
3.36, 3.37 & 3.40). Since bortezomib was also shown to activate the apoptotic 
pathway at similar doses (Fig. 3.34 & 3.35), it was hypothesized that the 
accumulation of misfolded N-CoR by bortezomib may activate unfolded 
protein response (UPR) in these cells, eventually leading to programmed cell 
death. As such, the effects of bortezomib on UPR were investigated next.  
UPR involves three signaling pathways which originate in the ER, mediated 
by three ER transmembrane proteins – inositol-requiring enzyme 1(IRE-1), 
pancreatic ER kinase (PKR)-like ER kinase (PERK), and activating 
transcription factor 6 (ATF6). As unfolded proteins accumulate in the ER, 
these proximal sensors are activated by their dissociation from ER chaperone 
GRP78, which leads to their activation and triggers the UPR. UPR is initially 
triggered to reduce accumulation of unfolded proteins to restore ER 
homeostasis. In cases where protein accumulation and ER stress persists 
beyond the folding capacity of the ER, UPR signaling switches from pro-
survival to pro-apoptotic.130,137  
Westerm blot analysis of UPR signaling pathways was carried out on MKN74 
cells treated with 50 nM bortezomib in a time-dependent manner, between 0-
24 hours. Activation of UPR via the PERK pathway was evident by the 
increased expression of phospho-PERK after 8 hours of treatment, which was 
accompanied by phosphorylation of eukaryotic initiation factor 2 α (eIF2α). 
Upregulation of growth-arrest and DNA-damage-inducible gene 34 
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(GADD34), a pro-apoptotic protein associated with ER stress-induced 
apoptosis, was also observed. It is also a protein-phosphatase 1 (PP1)-
interacting protein that induces PP1 to dephosphorylate eIF2α, thus relieving 
the translational block mediated by phosphorylated eIF2α. This explains the 
attenuation of eIF2α phosphorylation observed at 24 hours of treatment (Fig. 
3.41). This negative feedback mechanism by GADD34 limits the translational 
block through phosphorylation of eiF2α by PERK, thus ensuring an efficient 
response to prolonged ER stress. Bortezomib treatment also activated the 
IRE1 pathway in MKN74 cells. After 4 hours of treatment, bortezomib 
induced phosphorylation of apoptosis signal regulating kinase 1 (ASK1), 
followed by phosphorylation of c-jun N-terminal kinase (JNK). JNK 
phosphorylation is accompanied by a concomitant increase in the 
phosphorylation of B cell lymphoma 2 (BCL2) (Fig. 3.42). The IRE1-ASK-
JNK pathway has previously been implicated in ER stress-induced cell 
death.192 Phosphorylation of BCL2 also inhibits its anti-apoptotic activity. 
That UPR was activated in bortezomib-treated MKN74 cells was further 
confirmed by the activation of ATF6 as seen by the detection of its cleaved, 
active form after 4 hours of treatment. Additonally, up-regulation of pro-
apoptotic protein BAK was observed after 4 hours of treatment (Fig. 3.43). As 
bortezomib has earlier been shown to result in caspase activation and PARP 
cleavage (Fig. 3.35), the data collectively suggests that bortezomib-mediated 
inhibition of misfolded N-CoR degradation may elicit ER stress via the 












Figure 3.41. Bortezomib activates the PERK pathway in MKN74 cells. MKN74 
cells were treated with 50 nM of bortezomib for 0 - 24 h. Western blot analysis was 
carried out using anti-phospho-PERK, anti-PERK, anti-phospho-elF2α, anti-elF2α, 
and anti-GADD34 antibodies. Level of β-actin expression was determined as an 















Figure 3.42. Bortezomib activates the IRE pathway in MKN74 cells. MKN74 
cells were treated with 50 nM of bortezomib for 0 - 24 h. Western blot analysis was 
carried out using anti-phospho-ASK, anti-ASK, anti-phospho-JNK, anti-JNK, anti-
phospho-BCL2, and anti-BCL2 antibodies. Level of β-actin expression was 


















Figure 3.43. Bortezomib activates the ATF6 pathway in MKN74 cells. MKN74 
cells were treated with 50 nM of bortezomib for 0 - 24 h. Western blot analysis was 
carried out using anti-ATF6 and anti-Bak antibodies. Level of β-actin expression was 




























4.1 GC011, an artemisinin derivative with TGF-β-like activity, is a 
promising therapeutic candidate for TGF-β sensitive gastric cancers. 
4.1.1 GC011 exhibits its potent growth inhibitory effects in TGF-β sensitive 
gastric cancer cells by sensitizing them to TGF-β-induced apoptosis. 
Given the paucity of modalities for the clinical treatment of gastric cancer, 
new approaches for therapeutic development are urgent and necessary. One 
possibility is drug repositioning, the process of finding new uses for existing 
drugs, which presents a safer and more economical approach as these drugs 
have already been proven safe for clinical use. In this context, one such 
promising compound is artemisinin, which has already been FDA-approved 
for the treatment of malaria and is well-tolerated without adverse side effects. 
Antitumor activity of artemisinin has already been documented in human trials 
111 and also in individual clinical cases.109,110,193 Artemether and artesunate 
have been used in cancer therapy with good tolerability and lack of significant 
side effects. In all, a large body of in-vitro and in-vivo finding has since 
demonstrated the usefulness of artemisinins against tumor cells derived from 
various subtypes of human malignancies, but relatively little mechanistic 
information has been presented. Of note, only one study to date has assessed 
its use in gastric cancer.180 In this report, we have presented evidence of potent 
growth inhibitory function of an artemisinin derivative on TGF- sensitive 
gastric cancer cells. The data observed in the MTS assay showed that 
treatment with 5 µM of GC011 for 96 hours was capable of inhibiting almost 
80% cell growth, which corresponded with a similar percentage of apoptotic 
cells observed at the same dose and treatment time. This suggests that the anti-
proliferative effect of GC011 on SNU16 cells was mainly by the activation of 
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the apoptotic pathway.  It is significant to note that GC011 did not 
demonstrate cytotoxic effects on normal gastric cancer cells, suggesting its 
specificity to cancer cells. As such, GC011 could be a promising cytotoxic 
agent for a selected group of TGF-sensitive gastric cancers. 
Although inactivation of TGF-signaling and resistance of cells to TGF- 
stimuli are linked to the carcinogenesis in several human tumors including 
gastric cancer, the effect of TGF- could also be pro-oncogenic, especially in 
the later stages of the carcinogenic process. The pro-oncogenic role of TGF-
is mainly manifested in the form of cellular resistance to TGF-stimuli 
which could indirectly result from the TGF--induced production of 
extracellular matrix, suppression of immune function, or promotion of 
angiogenesis. Interestingly, artemisinin has also been shown to downregulate 
the expression of oncogenic TGF-β target genes such as MMPs 118. It would 
therefore be interesting to study if GC011 and other artemisinin derivatives 
could downregulate these oncogenic TGF-β target genes in gastric cancer cells 
as well. 
In addition, TGF-resistance could also result from the mutation or 
inactivation of TGF-βreceptors or Smad proteins, as well as silencing of TGF-
β target genes. In particular, down-regulation of Smad3 expression was 
associated with TGF-resistance in a gastric cancer derived cells SNU-484, 
and when Smad3 was ectopically expressed in SNU-484 cells, the cells 
became TGF-β sensitive.181 These findings suggest that TGF-β resistant 
tumors could be sensitized to the growth inhibitory effects of TGF-β through 
the therapeutic restoration of function of Smad-TGF-pathway. In this study, 
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it was demonstrated that the selective antitumor effects of GC011 in SNU16 
cells was apparently mediated by the activation of Smad-dependent up-
regulation of TGF-β target genes p21 and PAI-1, suggesting that GC011 could 
restore the deregulated Smad-dependent TGF-signaling in TGF-β sensitive 
gastric cancer cells. Additionally, it was also found that GC011 upregulated 
the expression of the TGF-β1 ligand (Fig. 3.11C), further suggesting that 
GC011 could exert its antitumor effects by activating or enhancing TGF-β 
growth inhibitory pathways.  
Although TGF-resistance is a universal phenomenon in most gastric cancer 
cells, this resistance is largely acquired during the later stage of the 
carcinogenic process.194,195 Therefore, despite its lack of effectiveness against 
TGF-resistant cells, GC011 could still be effective against majority of 
gastric cancer if used during the early stage of the carcinogenic process. 
Moreover, the possibility that GC011 can sensitize TGF- resistant cells to 
apoptosis at higher concentration cannot be ruled out and needs to be 
investigated. Therefore, further investigation with GC011 and other 
artemisinin derivatives 103,179 will be required in order to evaluate their full 
therapeutic potential in gastric cancer. 
4.1.2 GC011 inhibits N-CoR-mediated transcriptional repression of TGF-β 
target genes. 
Several studies have postulated the involvement of N-CoR in the negative 
regulation of TGF-β signaling. In the absence of ligand stimulation, N-CoR, 
together with the other components of the repressor complex, such as SnoN 
and HDAC, is recruited to the promoter of TGF-β target genes. Upon ligand 
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binding, this repressive complex is removed, thus allowing transcriptional 
activation of the genes to proceed.184 It was shown in this report that ligand 
stimulation of the TGF-β signaling pathway, whether by GC011 and TGF-β1, 
could induce the degradation of N-CoR and HDAC1 in TGF-β sensitive cells, 
similar to the ligand-induced degradation of SnoN.184 N-CoR ablation also led 
to the activation of the promoter of the TGF-β responsive gene, suggesting 
that transcriptional activity of TGF-β target genes may be regulated by N-
CoR. Further studies need to be carried out to establish the role of N-CoR on 
promoter activity of TGF-β target genes, and also investigate the action of 
GC011 on the other known components of the N-CoR transcriptional 
repression machinery, such as MeCP2, Ski/SnoN and other HDACs. 
Of significance, N-CoR was found to be mislocalised in TGF-β resistant 
SNU5 cells, in contrast to its nuclear localisation in TGF-β sensitive SNU16 
cells. As nuclear N-CoR appears to be sensitive to GC011-induced 
degradation, while cytoplasmic N-CoR is not, it is tempting to speculate if N-
CoR localisation may be a good marker for the identification of the subset of 
gastric tumors that might be amenable to GC011 treatment.  
4.1.3 Runx3 induces degradation of N-CoR via the ubiquitin-proteosome 
pathway and possibly regulates N-CoR-mediated repression of TGF-β target 
genes. 
Runx3 is a tumor suppressor strongly implicated in gastric cancer and other 
epithelial cancers, and has been established as a downstream target of the 
tumor suppressive TGF-β pathway. It was found that Runx3 expression was 
diminished in a majority of gastric cancers due to hemizygous deletion and 
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hypermethylation of its promoter,62 and its aberrant localisation in gastric 
cancer cell lines was also reported.19 Consistent with these reports, this study 
determined that Runx3 was not expressed in most of the gastric cancer cell 
lines, except for TGF-β sensitive cell line SNU16. Given the role of N-CoR in 
DNA-dependent methylation repression,85 initial investigations were carried 
out to determine if epigenetic regulation of Runx3 might be mediated by N-
CoR. Instead, it was found that Runx3 induced the cytoplasmic translocation 
of N-CoR and its subsequent degradation via the ubiquitin-proteosome 
pathway. This in turn would relieve target genes from transcriptional 
repression. While it is currently unknown how Runx3 mediates the 
degradation of N-CoR through the UPP, it is possible that Runx3 is a putative 
E3 ubiquitin ligase. Nevertheless, these findings may be able to provide novel 
insights into transcriptional regulation by these two distinct classes of 
molecules and their possible interactions. As Runx3 has previously been found 
to upregulate proapoptotic Bim and p21 via the TGF-β pathway,72,73 it is 
speculated that Runx3 might regulate N-CoR-mediated repression of TGF-β 
target genes by inducing its degradation via the UPP. Initial work in this study 
revealed that N-CoR overexpression abrograted Runx3-induced activation of 
TGF-β responsive promoter, IgCα, suggesting a mechanistic link between 
these two molecules in TGF-β gene transcriptional activity. Further work 
needs to be carried out to explore this link.  
4.2 Bortezomib therapeutically targets the UPR pathway in gastric cancer 
by inhibiting the degradation of misfolded N-CoR. 
4.2.1 Gastric cancer cells harbor an APL-like misfolded conformational 
dependent loss of N-CoR.  
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Previously, our laboratory has reported a role of misfolded conformation 
dependent loss (MCDL) of N-CoR in the pathogenesis of acute promyelocytic 
leukemia (APL).187 Other studies in our laboratory identified an APL-like 
MCDL loss of N-CoR in acute monoblastic leukemia (AML-M5)196 and non-
small cell lung cancer (NSCLC)197, and subsequently identified inhibition of 
N-CoR misfolding as an attractive strategy for treatment. It was therefore 
hypothesized that an APL-like MCDL of N-CoR might be a common feature 
in malignancy. Indeed, initial screening of N-CoR in gastric cancer cell lines 
revealed the post-transcriptional loss of N-CoR in most of the cell lines, and a 
down-regulation of N-CoR protein expression in most gastric tumor tissues. 
Subsequent experiments showed that majority of N-CoR in gastric cancer cell 
lines displayed characteristics of misfolded N-CoR similar to that seen in 
APL,187 such as aberrant cytoplasmic localization, detergent insolubility and 
amplification of ER stress. A similar down-regulation and mislocalisation of 
N-CoR was also detected in gastric tumor tissues, indicating that MCDL of N-
CoR was not exclusive to gastric cancer cell lines.  
It was previously demonstrated that fusion protein PML-RAR-induced 
aberrant post-translational modification of N-CoR contributed to its 
misfolding in APL.187 Initial investigations in this study suggested that 
misfolded N-CoR observed in gastric cancer may also have been an outcome 
of aberrant post-translational modification, specifically serine-threonine 
phosphorylation, although the underlying oncogenic events are currently not 
known. SMRT, another transcriptional corepressor closely related with N-
CoR, has been reported to be regulated by several SMRT-targeting serine-
threonine kinases, including IKKα and MEKK-1, leading to their cytosolic 
153 
 
translocation,94,190,191 but few N-CoR-targeting kinases have been identified. It 
would therefore be of great interest to further investigate the role of kinases in 
the regulation of N-CoR stability and function, and also the underlying 
mechanism leading to it.  
Although the question of whether MCDL of N-CoR in gastric cancer can 
contribute to the malignant growth and transformation of gastric cancer cells 
has yet to be answered, given the active involvement of N-CoR regulation in 
several cellular pathways, misfolding of N-CoR may have several tumor-
promoting consequences. A possible consequence is the loss of normal tumor 
suppressive function of N-CoR due to its misfolding. As observed in TGF-β 
sensitive gastric cancer cell lines, N-CoR is functional and plays a role in the 
regulation of the tumor suppressive pathway of TGF-β signaling. It is possible 
that loss or misfolding of N-CoR may contribute to TGF-β resistance, thus 
promoting survival of early cancer cells. Misfolded N-CoR may also lead to 
the loss of its suppressive function on other oncogenic pathways, such as the 
PI3K/Akt/mTOR pathway, contributing to the survival and growth of cancer 
cells, such as that seen in thyroid tumor cell.95 Another mechanism has been 
identified in APL, whereby autophagic degradation of misfolded N-CoR 
neutralized ER stress and thus protected the cells from ER stress-induced 
apoptosis (Fig. 4.1).197 Further investigations on the effects of N-CoR 
misfolding in gastric cancer should be carried out to provide new insights into 
the molecular aspects of gastric cancer development and aid in development of 






Figure 4.1. Possible contributions of misfolded N-CoR to the transformation and 
malignant growth of cancer cells. The misfolded conformation dependent loss of N-
CoR can contribute to the malignant growth and transformation of gastric cancer cells 
through multiple mechanisms; such as loss of normal tumor suppressive function of 
N-CoR due to misfolding, neutralization of ER stress due to the degradation of 
misfolded N-CoR and possible activation of oncogenic pathways due to loss of its 
suppressive function. P/T: post-translational; N-CoR: nuclear receptor co-repressor; 
UPR: unfolded protein response; CMA: chaperone-mediated autophagy; PI3K: 






4.2.2 Bortezomib induces cytotoxic UPR by inhibiting proteasome-mediated 
degradation of misfolded N-CoR in gastric cancer. 
In mammalian cells, a coordinated biochemical response to the accumulation 
of misfolded proteins within the ER termed the unfolded protein response 
(UPR) exists to maintain ER homeostasis.130 This cellular response to ER 
stress consists of two branches; on one hand it induces cytoprotective 
pathways to re-establish homeostasis, such as enhancing protein folding 
capacity through upregulation of ER chaperone proteins and enhancing 
degradation of misfolded proteins via ER-associated degradation (ERAD).152 
On the other hand, if the ER stress is prolonged and unresolved, signaling 
pathways that promote apoptosis are activated.133 In tumor cells which grow 
under oncogenic stress conditions such as accumulation of misfolded proteins, 
there is a great reliance on the cytoprotective UPR for survival 154. In contrast, 
most normal cells are not subject to stress, and the UPR pathways are inactive. 
This selective importance of UPR in the maintenance of malignancy has 
therefore provided a therapeutic window for agents targeting the UPR as an 
anticancer strategy. 
In this study, gastric cancer cells harboring the misfolded N-CoR displayed 
high constitutive expression levels of ER resident chaperones GRP78 and PDI 
compared to SNU16, which expressed native N-CoR in the nucleus. The 
prevalent loss of N-CoR in these cells also suggested its degradation via the 
ERAD pathway. Although the levels of N-CoR protein in all the gastric cancer 
cell lines were substantially lower than that in TGF-β sensitive SNU16 cells, 
the gastric cancer cells displayed differential expression of N-CoR. It is 
possible that the cells in which some N-CoR expression was still detected 
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were still in the early stages of the misfolding process (Fig. 4.2), and were 
therefore not subjected to ERAD yet. Proteasomal degradation of misfolded 
proteins retrotranslocated from the ER to the cytosol represents the final step 
in ERAD.152 It was therefore postulated that disruption of the ERAD pathway 
via proteasome inhibition may result in the accumulation of the misfolded N-
CoR, thus triggering ER stress and ultimately, the induction of terminal UPR, 
that is, cell death. Bortezomib is the first proteasome inhibitor developed 
successfully for anti-cancer therapy.163 Experiments were carried out to 
investigate the anticancer effects of bortezomib on gastric cancer cells and its 
effects on the misfolded N-CoR and the UPR pathways. As expected, 
bortezomib treatment significantly inhibited proliferation of gastric cancer 
cells. Of note, this cytotoxicity observed in gastric cancer cells was achieved 
at very low doses (nM) which were not cytotoxic to the normal human gastric 
cancer cell line, HFE-145. Although bortezomib was effective in inhibiting 
proliferation of most gastric cancer cell lines after 48 hours with a low dose of 
50 nM, the cell lines displayed different levels of sensitivity to bortezomib at 
24 hours. One reason could be that the cells are at different levels of ER stress, 
depending on the accumulated misfolded protein load present in each cell line.  
Previous studies have shown that bortezomib induces caspase-dependent 
apoptotic cell death in MM cells.172 In line with these reports, the cytotoxic 
effects of bortezomib in gastric cancer cells were also found to be associated 
with the induction of the apoptotic pathway, via the activation of caspase-9, 
caspase-3 and PARP cleavage. In addition, bortezomib also promoted the 
accumulation of misfolded N-CoR in these cells, which was accompanied by 
activation of ER stress reflected by the formation of high molecular weight 
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PDI, HSP60 and GRP78. Evidence that bortezomib sensitized gastric cancer 
cells to UPR-induced apoptosis, or terminal UPR, was reflected in the 
activation of the IRE1-ASK1-JNK pathway with bortezomib treatment, and 
inhibition of anti-apoptotic BCL-2, thus committing the cells to ER stress-
induced cell death. Pro-apoptotic BAK and GADD34 proteins were also up-
regulated by the activation of the PERK and ATF6 pathways respectively.  
In addition to its proteasome inhibitory function, it is possible that bortezomib-
induced apoptosis of gastric cancer cells may involve other mechanisms such 
as that reported in melanoma and prostate cancer cells.177,178 This could 
explain in part why bortezomib was also found to promote cytotoxic effects in 
TGF-β sensitive cells, SNU16 and SNU620, which lack misfolded N-CoR. 
Alternatively, bortezomib may induce accumulation of other misfolded 
proteins present in gastric cancer. Although the proteasome inhibitory function 
of bortezomib has been well-established in MM and other cancers, it is yet to 
be shown in gastric cancer cells. The inhibitory effect of bortezomib on 
proteasome function in gastric cancer cells was therefore analysed and it was 
found that bortezomib significantly inhibited all three proteolytic activities of 
the proteasome in MKN74 cells in a dose- and time-dependent manner, further 
establishing its potent activity as a proteasome inhibitor in various tumors. In 













Figure 4.2. Representation of the different stages of N-CoR misfolding in gastric 
cancer cells. The misfolding of N-CoR in gastric cancer cells is initiated by yet to be 
identified oncogenic stimuli, which results in the post-translational modification of 
the native N-CoR in these cells, such as serine-threonine phosphorylation, leading to 
a conformational change in N-CoR. The misfolded N-CoR is then exported out of the 
nucleus, where it accumulates until it reaches threshold levels that trigger 
proteasome-mediated degradation in the cytoplasm. PTM: post-translational 













4.3. Concluding remarks 
Multiple signaling pathways have been implicated in gastric carcinogenesis, 
and it is increasingly clear that dysregulation of these intracellular signaling 
pathways represent a common pathogenic mechanism in gastric cancer. An 
important signaling pathway which has been widely implicated in gastric 
carcinogenesis is the transforming growth factor-β (TGF-β) pathway, which is 
involved in various biological processes such as cell proliferation, 
differentiation, migration and apoptosis. The pleiotropic effects of this 
pathway are regulated by its interactions with adaptor proteins, ubiquitinators 
and various transcriptional factors. One such factor is the nuclear receptor co-
repressor (N-CoR), whose role in regulating transcriptional repression of TGF-
β target genes has been postulated in several studies. Another molecule, 
transcription factor Runx3, is a downstream target of TGF-β signaling 
pathway and its tumor suppressor role in gastric cancer has been firmly 
established.  
In this thesis, the therapeutic potential of the artemisinin derivative GC011 on 
various gastric cancer-derived cell lines was investigated, shedding new light 
into dysregulation of TGF-β signaling pathway in gastric cancer and also 
highlighting the therapeutic potential of GC011 in TGF-β sensitive gastric 
cancers. It was found that GC011 induced selective growth inhibition and 
promoted apoptosis in TGF-β sensitive gastric cancer cells. The pro-apoptotic 
effect of the GC011 was apparently mediated though the activation of Smad3-
dependent up-regulation of known TGF-β target genes PAI-1 and p21. GC011 
also demonstrated a stimulatory effect similar to TGF-β on the promoter of a 
bona fide TGF-β target gene IgCα that contains a consensus TGF-β response 
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element. GC011-induced activation of TGF-β targets apparently resulted from 
the abrogation of N-CoR meditated transcriptional repression of TGF-β 
promoter as GC011 promoted a selective degradation of N-CoR/HDAC1 
protein in TGF-β sensitive cells. RUNX3 was found to induce the proteasome-
mediated degradation of N-CoR. These findings highlight the therapeutic 
potential of GC011 as a putative TGF-β analogue in TGF-β sensitive gastric 
cancer cells.  The proposed action of GC011 on TGF-β sensitive gastric cancer 
cells is summarized in Figure 4.3. 
As GC011 is only effective in TGF-β sensitive gastric cancer cells, alternative 
therapeutic approaches that would be effective in a wider scope of gastric 
cancers are needed. Our lab has previously identified a role for misfolded 
conformational dependent loss (MCDL) of N-CoR in the pathogenesis of APL 
cells, and subsequently in AML-M5 and NSCLC cells since, suggesting that 
misfolded N-CoR is a general trait of malignant cells. Indeed, the findings in 
this thesis suggested that a similar MCDL of N-CoR is also prevalent in 
gastric cancer cells. As in APL cells, misfolded N-CoR in gastric cancer cells 
are likewise cytoplasmic, detergent-insoluble, post-translationally modified, 
and are associated with ER stress amplification. Given that tumor cells are 
heavily reliant on the UPR pathway to promote the degradation of misfolded 
proteins via the ERAD pathway, the current study assessed the antitumor 
activity of a proteasome inhibitor bortezomib in gastric cancer cells. The 
results showed that bortezomib inhibited the degradation of misfolded N-CoR 
in gastric cancer cells, resulting in its toxic accumulation, ultimately leading to 
the induction of terminal UPR in these cells. These findings suggest that 
proteasome inhibition is a promising strategy in gastric cancer, and identifies 
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bortezomib as a potential candidate for the treatment of gastric cancer. Also, 
gastric cancer cells may have a low threshold for proteosomal inihibitor-
induced UPR activation and ER stress-induced apoptosis due to the presence 
of misfolded N-CoR. A summary of these findings is represented in Figure 
4.4.  
These novel findings presented in this thesis therefore not only provide 
mechanistic insights into the antitumor activities of artemisinin and 
bortezomib in gastric cancer cells, but also further delineate the underlying 
molecular pathways which might facilitate future strategies to enhance 















Figure 4.3. Proposed mode of action of artemisinin derivative on TGF-β target 
genes in TGF-β sensitive gastric cancer cells. In the nuclei of unstimulated TGF-β 
sensitive gastric cancer cells, transcriptional repressors Ski and SnoN binds to 
repeated AGAC or GTCT elements on TGF-β target gene promoters together with 
Smad3/4, and recruits transcriptional corepressor N-CoR and its associated repressor 
complex including HDAC1. In the absence of a signal, transcriptional activity of 
these genes are inhibited by this repressor complex. Upon GC011 treatment, the 
TGF-β signalling pathway is activated which induces Runx3 to mediate the 
cytoplasmic export of N-CoR and its subsequent proteosomal degradation, thereby 
displacing the N-CoR-HDAC1-repressor complex from the promoter of the TGF-β 
target genes. This in turn would allow activators to bind and activate transcription of 




















Figure 4.4. Targeting the action of ERAD pathway on misfolded N-CoR in 
gastric cancer cells with proteasome inhibitor, bortezomib. In response to 
unknown oncogenic stimuli, aberrant phosphorylation of N-CoR takes place, 
resulting in its misfolded conformation in gastric cancer cells. In a functioning UPR 
pathway, misfolded N-CoR is then exported to the cytoplasm where its accumulation 
eventually triggers its degradation via the ERAD pathway. Proteasome inhibition by 
bortezomib inhibits the ERAD pathway, thus leading to a toxic accumulation of 
misfolded N-CoR in gastric cancer cells. This results in the amplification of ER 
stress, eventually leading to the induction of ER stress-induced apoptosis. Thus, 
proteasome inhibition presents an attractive therapeutic approach in gastric cancer. 
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